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Chapter 1 
INTRODUCTION 
In response to Iraq's invasion of Kuwait in 1990, the United States deployed 
approximately 697,000 military personnel in Operations Desert Shield and Desert Storm 
from August 1990 to June 1991. After returning from the Persian Gulf War (GW), 
thousands of US military personnel have complained of a variety of symptoms including 
persistent fatigue, headaches, muscle and joint pain, sleep disturbances, cognitive 
difficulties and others (Joseph, 1997; Haley and Kurt, 1997). Epidemiological studies 
showed that these symptoms were reported more frequently in the GW veterans than in 
those who were not deployed (Joseph, 1997). As Table 1 shows, the wide array of the 
symptoms ranges from minor conditions such as fatigue or headache to some more 
serious disorders e.g. memory, sleep or concentration problems. One characteristic of the 
reported illnesses is that complaints from veterans can non-specifically be associated with 
multiple conditions, e.g. 1) headache might be caused by a lack of oxygen supply to the 
brain, intoxication from biological or chemical agents, or common migraine, 2) joint and 
muscle pain could arise from the common cold, bacteremia, rheumatoid arthritis or a 
number of other medical conditions. Another characteristic is that these illnesses have a 
poor organic or systemic explanation and appear to be disturbances of multiple systems. 
1 
Symptoms As chief complaint % As any complaint % 
Fatigue 20 59 
Headache 9 44 
Memory problems 6 40 
Sleep disturbances 5 40 
Rash 4 30 
Joint pain 4 47 
Shortness of breath 2 19 
Abdominal pain 1 16 
Muscle pain 1 22 
Difficulty concentrating 1 31 
Diarrhea 0.5 18 
Depression 0.3 22 
Cough 1 1 
Table 1: The most frequent symptoms among 3558 Comprehensive Clinical Evaluation 
Program participants with a Primary Diagnosis of "Symptoms, Signs, and Ill-Defined 
Conditions" (Adopted from Joseph, 1997). 
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Based on a study involving 249 soldiers from the Gulf War, Haley and coworkers (1997 
a, b) identified and characterized the "syndromes" into 6 categories: 1) impaired 
cognition, 2) confusion-ataxia, 3) arthro-myo-neuropathy, 4) phobia-apraxia, 5) fever-
adenopathy, and 6) weakness-incontinence. The first 3 syndromes are considered the 
major, involving the central nervous system (CNS) functions. 
The exact mechanisms for the Gulf War Illnesses (GWI) are still not clear. 
Several risk factors have been postulated to contribute to the development of GWI 
including infectious diseases, pyridostigmine (PYR) toxicity, immunizations, stress, 
chemical and biological warfare agents, oil well fires, depleted uranium and pesticides. 
Among these possible etiological factors, we were particularly interested in the 
hypothesis that stressors increase BBB permeability and allow PYR penetration into the 
CNS to cause central cholinergic dysfunction. 
PYR is a carbamate cholinesterase (ChE) inhibitor. It was approved by the United 
States Food and Drug Administration (FDA) in 1955 as a therapeutic agent for 
myasthenia gravis, an autoimmune disease characterized by gradually developing muscle 
weakness and fatigability (Breyer-Pfaff et al., 1985; Drachman, 1994; Antonini et al., 
1996). As an effective therapeutic for myasthenia gravis, PYR is given initially at a 
dosage of 60 mg 3 times a day. The dosage is increased until the maximum clinical 
benefit is reached. The average dose of PYR given orally is around 600 mg/day with a 
dose range from 200 to 1400 mg/day. 
During the GW from 1990 to 1991, PYR bromide tablets, under the status of 
"investigational new drug" conferred by FDA, were given to United States and allied 
military personnel as a pretreatment to protect against possible organophosphorus (OP) 
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nerve agent (e.g., soman) attack from Iraq (Keeler et al., 1991; Gunderson et al., 1992). 
The military doctrine for PYR use as prophylactic agent against OP nerve gas is 
administration as oral tablet, at a dosage of 30 mg every 8 hours. PYR could be given for 
up to 2 weeks as long as the soldiers were under high risk of nerve agent attack. Few 
adverse effects were reported while PYR used as drug for either Myasthenia Gravis at 
lower end of dose range or for military purpose before GW. 
PYR is a charged drug and has been reported to have relatively poor and erratic 
absorption into the circulation from the gastrointestinal tract. First-pass metabolism also 
contributes to the low bioavailability of PYR. A previous study (Aquilonius et al., 1980) 
of PYR pharmacokinetics in human volunteers suggested the kinetic constants ( e.g. 
elimination half-life, volume of distribution, and plasma clearance) were very similar 
between 2.5 mg intravenous injection and 120 mg oral administration, giving the 
bioavailability of about 7.6%. Most of the PYR given orally is excreted in feces 
unchanged while most of the absorbed PYR is excreted in the urine in the original form 
(Keeler, 1990). A small portion of the PYR is mainly metabolized into 3-hydroxy-N-
methyl pyridium, which is both a ChE inhibitor and acetylcholine (ACh) receptor 
antagonist (Lee et al., 1992). 
The rationale for PYR use as pre-exposure antidote to OP nerve agent relies on 
the short duration of action of PYR on acetylcholinesterase (AChE). As shown in Figure 
1, the interaction between AChE and its natural substrate (ACh) or inhibitors (carbamate 
or OP) can be illustrated in three steps, with the difference between substrate and 
inhibitors primarily in the reaction rate of the final step. With PYR, this reaction rate is 
slower than that for ACh but much faster than for OPs. Therefore, PYR is 
4 
EOH+AX EOH•AX EOA 
Figure 1: Reaction of AChE with either the natural substrate (acetylcholine) or inhibitors 
( carbamate or OP). EOH represents AChE. AX represents acetylcholine, carbamate or 
OP. In structure of AX (substrate or inhibitor), A is binding group while Xis the leaving 
group. 
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referred to as a "reversible" ChE inhibitor while OPs are referred to as "irreversible" 
inhibitors. Reversible inhibition of ChE by PYR prevents the irreversible inactivation by 
an OP. This forms the basis for the rationale for PYR prophylaxis against OP chemical 
warfare agent exposure. Soman, one of the OP nerve agents, leads to lethality by 
irreversibly inactivating AChE. Pretreatment with PYR complexes a certain proportion of 
the AChE molecules. Occupancy of PYR on AChE prevents the further binding on the 
same active site by an OP. After withdrawal from OP exposure, PYR-AChE complex 
undergoes hydrolysis and decarbamylation since PYR has a short duration of action, 
regenerating the AChE activity. PYR given to soldiers as during GW caused about 20 to 
40% ChE inhibition, which assures this portion of AChE molecules are unavailable for 
inhibition by an OP. On the other hand, the remaining AChE molecules (60 to 80%) 
would be generally sufficient for normal function without compromising performance or 
eliciting side effects associated with AChE inhibition. Compared to other carbamates 
such as physostigmine, PYR is preferred as a protective agent because it is not expected 
to enter the CNS and influence brain function. PYR therefore does not significantly 
impair higher order mental performance. 
Atropine and pralidoxime (2-P AM), used as post-exposure antidotes, are the 
traditional therapeutic agents against nerve agent poisoning. Pralidoxime, however, is not 
effective in treating OP poisoning once "aging", a process in which AChE is permanently 
inactivated by the bound OP inhibitor, occurs. Therefore, pretreatment with PYR can 
protect the AChE molecules against an OP such as soman that ages rapidly. Since only 
minutes are needed for soman to irreversibly inhibit 50% of ChE, aging by the bound 
soman could occur before an intoxicated soldier could administer post-exposure 
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treatments. PYR administered prophylactically is therefore an effective and 
complementary adjunct to atropine and pralidoxime as treatment for OP intoxication with 
very rapid inhibitory effects on AChE activity. 
An overdose of either PYR or OP elicits toxicity by AChE inhibition, which leads 
to disturbances of cholinergic signaling. Figure 2 demonstrates the normal cholinergic 
signal transduction at the neuronal synapse. ACh is formed from the 2 immediate 
precursors, choline and acetyl coenzyme A by the catalytic enzyme choline-acetyl 
transferase. The reaction rate is determined by the availability of choline, which is 
supplied· from the plasma and through high affinity choline uptake following degradation 
of ACh. The synthesized ACh is concentrated in neurotransmitter vesicles within the 
presynaptic terminal. A slow release of ACh is considered as baseline release for "house-
keeping" purposes and occurs at all cholinergic synapses at rest condition. When a 
neuron fires, an action potential propagates to the presynaptic terminal. Depolarization 
initiates opening of the voltage-sensitive calcium ion channels. The resulting elevation of 
Ca++ ions triggers the fusion of neurotransmitter vesicles with the presynaptic membrane 
and subsequent release of ACh into the synaptic cleft. ACh binds with and activates 
cholinergic receptors on the postsynaptic membrane inducing the physiological events, 
e.g., gland secretion, muscle contraction or further downstream signaling through second 
messenger formation. AChE hydrolyzes ACh thereby terminating the action of the 
neurotransmitter. 
There are two maJor subtypes of cholinergic receptors located on the post-
synaptic membrane, nicotinic and muscarinic classified originally by the high affinity of 
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Presynaptic terminal 
ACh ChE ..,Choline + Acetyl-CoA 
r~ 
Postsynaptic terminal 
Figure 2: Cholinergic signal transduction at neuronal synapse. M-® and N-® represent 
muscrarinic and nicotinic receptor, respectively. 
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2 natural compounds (nicotine and muscarine) that bind to these receptors. Nicotinic 
receptors are essentially found in the CNS, autonomic ganglia, skeletal muscles and the 
adrenal glands. Most nicotinic ACh receptors consist of 5 peptide subunits, 2 copies of a 
subunits and a single copy of B, y or 8 subunit. The 5 protein subunits are arranged 
around a central cavity, which is the channel for the passage of ions across the 
membrane. Once the nicotinic receptor is activated by ACh, the ion channel is opened for 
the flow of selective ions. Therefore, the nicotinic ACh receptor is referred to as a 
"ligand-gated ion channel". Muscarinic ACh receptors are mainly located in the CNS 
(some presynaptic sites), myocardium, smooth muscles, and exocrine glands. In contrast 
to nicotinic receptor, the muscarinic receptor is a single polypeptide with 7 
transmembrane domains, by which the signal is transduced by interacting with associated 
G-proteins. · Upon binding with agonists, activation of muscarinic receptors generally 
causes inhibition of adenylyl cyclase or stimulation of phospholipase C, followed by the 
biochemical events including decreased production of cyclic AMP, and increased 
formation of inositol 1,4,5-trisphosphate and diacylglycerol, respectively. The change of 
the amount of these second messengers will affect other metabolic sequelae and trigger 
diverse cellular responses. 
In the presence of anti-ChE agents, AChE is inactivated and therefore unable to 
hydrolyze ACh. Consequently, ACh accumulates in the synapse and over-stimulates the 
cholinergic receptors on the postsynaptic membrane leading to cholinergic toxicity. The 
cholinergic toxicity could be either central or peripheral in nature. Central nervous 
system disturbances include emotional !ability, anxiety, headache, excessive dreaming, 
convulsion, ataxia, memory difficulty, respiratory paralysis and coma (Gutmann and 
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Besser, 1990). The peripheral cholinergic toxicity caused by overstimulating nicotinic 
receptors includes muscle involuntary movements such as twitches, fasciculation, 
cramps, and tremor followed by muscle weakness and paralysis leading to breathing 
difficulties and respiratory failure. Overstimulation of the peripheral muscarinic receptors 
leads to 1) smooth muscle spasms and increased gastrointestinal motility, nausea, 
vomiting abdominal cramping, bronchospasm and ureteral spasm etc, 2) extensive 
glandular secretion such as salivation, lacrimation, urination, defecation, rhinorrhea and 
bronchorrhea. 
PYR has a quaternary ammonium group in the molecule as shown in Figure 3. 
This drug is therefore positively charged at physiological pH. In contrast to another 
carbamate ChE inhibitor physostigmine (PHY) with central ChE inhibitory capability, 
PYR is not expected to enter the brain due to the restriction by the blood-brain barrier 
(BBB) from entrance of polar or large molecules into the CNS. 
The BBB consists of cerebral endothelial cells and the associated accessory 
structures including the tight junctions between endothelial cells, pericytes, astrocytes 
and the basal membrane. Figures 4 and 5 demonstrate the longitudinal and cross-
sectional views of the blood vessels in the brain. The endothelial cells and the tight 
junctions between them completely enclose the blood lumen forming a barrier that 
distributes along the length of the blood circulation in the brain. The basal membrane 
covers the abluminal surface of the endothelial cells, with the pericytes providing 
mechanical support to the endothelium. Pericytes associated with the blood vessels have 
been suggested to regulate endothelial cell proliferation, survival, migration, 
differentiation, vascular branching, thus essentially to maintain the normal morphology 
10 
H C . 
3 "' N-C-Q----r / 
H3C 
0 
Figure 3: Molecular structure of pyridostigmine. 
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Astrocyte Tight Junction Endothelial Cell 
Figure 4: Longitudinal view of blood capillaries in the brain. 
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Brain 
Astrocyte Tight Junction Endothelial Cell 
Figure 5: Cross-sectional view of the blood capillaries in the brain. 
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and function of the brain microvessels (Lindahl et al., 1997; Gerhardt et al., 2000; 
Hellstrom et al., 2001). Astrocytes are glial cells. With the end foot sharing the basal 
membrane, astrocytes cover most of the outer surface of the BBB endothelium and form 
another layer. Association of astrocytes with 'the endothelium is also important to the 
development and function of the BBB (Arthur et al., 1987; Wolburg et al., 1994). 
The tight junction is the key structure for maintenance of BBB integrity. It seals 
the clefts between endothelial cells at the apical region forming continuous physical 
strands that course through the brain vasculature. The tight junctions and the neighboring 
endothelial cells form a remarkably high transmembrane electrical resistance in the range 
of 1000 to 2000 ohms-cm2, as compared to less than 50 ohms-cm2 of transmembrane 
electrical resistance of the capillaries in other tissues (Butt et al., 1990; Cereijido et al., 
2000). The high electrical resistance at the blood-brain interface significantly limits 
molecule transport across the endothelial cells in the brain. Anatomy of cerebral 
endothelial cells shows 1) the cytoplasm is relatively similar in thickness and has very 
few pinocytotic vesicles that allowing formation of vacuole for molecule transport, 2) 
lack of fenestrations as noted in the capillaries in peripheral tissues and thus less openings 
for chemical penetration, 3) more and larger mitochondria (Oldendorf and Brown, 1975; 
Oledndorf et al., 1977) resulting ~n enhanced energy production capability, which is 
believed to be required for active transport of "favorable" substances into the brain. 
These anatomical characteristics suggest that blood to brain molecule transport is more 
favored of energy-dependent active transport over free diffusion, which allows the brain 
to gain necessary while rejecting unwanted substances. 
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The BBB strictly regulates and limits the exchange between the circulation and 
the cerebral extracellular space. To pass from the blood stream to the brain parenchyma, a 
molecule needs to penetrate in order 1) luminal membrane of endothelial cell, 2) the 
cytoplasma of the endothelial cell, 3) the abluminal membrane of the endothelial cells, 4) 
pericytes, basal membrane or both. 
While relatively small or lipophilic molecules could pass the barrier through the 
clefts between endothelial cells or directly through the endothelial cells, other types of 
molecules have little access into the CNS. This mechanism protects the brain from 
composition changes that may result in pi;ithophysiological events such as edema or 
swelling in brain tissues. The BBB integrity is maintained by the continuous tight 
junction expressed by the endothelial cells (Brightman and Reese, 1969). The compound 
of interest for our studies, PYR, has little access into the CNS under normal conditions. 
Some recent studies, however, suggested that stressful conditions may increase BBB 
permeability and allow PYR to enter the brain causing cholinergic toxicity. 
Stress is stimulation or pressure from the ever-changing environment and the 
associated imbalance between exogenous environment demands and the living system's 
internal adaptation capacity. Existence of stress has allowed the organism to evolve 
strategies to deal with the critical changes of the surrounding environment. Stress of 
limited degree and duration is believed to have generally positive effects on living 
system. For instance, stressors may increase mental and physical performance, prepare 
the organism for high energy needs etc. A number of studies suggested, however, 
extreme and persistent stress caused adverse effects including injury or disturbance of 
brain structures or functions (Magarinos et al., 1996; McEwen and Magarinos, 1997; 
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Fuchs and Flugge, 1998; McEwen, 1999; McEwen, 2000). Specifically, stress was found 
to compromise the BBB integrity and facilitate chemical toxicity in the CNS. 
Friedman and coworkers (1996) reported a critical finding that initiated 
significant interest and extensive studies ih effects of stress on BBB permeability and 
PYR penetration into the CNS. In Friedman's work, adult FVB/N mice were subjected to 
2 periods of 4-min forced swim with a 4 min rest between the 2 stress sessions. Ten 
minutes after the last swim, mice were injected with either saline or PYR and brain ChE 
activity was measured 10 min after PYR exposure. Results showed the dose of PYR 
needed to cause 50% brain ChE inhibition under normal condition was 1.50 mg/kg 
whereas the equi-effective dose was reduced to 0.01 mg/kg following the forced swim 
stress. The greater than 100 fold change in PYR ED50 under normal and stressful 
conditions suggested a robust penetration of PYR into the CNS, presumably due to BBB 
disruption by the brief physical stress. Friedman and colleagues (1996) also evaluated 
BBB permeability after the acute sessions of swim stress by doing the following 
experiments. In one study, Evans blue dye was injected into the heart of the mice and the 
concentration of albumin-bound Evans blue in the brain was determined 
spectrophotometrically. Data suggested the leakage of Evans blue dye into the brain of 
the stressed mice increased 10 times compared to that of the non-stressed mice. In 
another study, cytomegalovirus (CMV) AChE plasmid was injected (i.p.) into stressed or 
non-stressed mice. PCR amplification showed the CMV AChE DNA was detected from 
cycle reaction 21 in stressed mice while the PCR products were weak from cycle reaction 
24 in non-stressed mice. Results suggested the penetration of plasmid DNA into the 
brains of the stressed mice was at least 8 times higher than that of the non-stressed mice. 
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Furthermore, central disruptions were noted. The level of PYR-induced c-fos oncogene 
was found to increase over 100 fold in the stressed mice compared to controls. In vitro 
incubation of brain slices with PYR caused similar enhanced c-fos mRNA level and 
neuronal excitability. Results from this study suggested forced swim stress facilitated 
PYR entry into the brain across a "leaky" BBB. 
Other studies also suggested a variety of physical stressors may compromise BBB 
integrity and increase barrier permeability. Physical immobilization caused the vital dye 
trypan blue to enter into brain areas such as hypothalamus and the reticular formation 
(Belova and Jonsson, 1982). Acute heat at 38°C for 4 hrs, chronic heat at 36°C, and 
continuous 30 min forced swim were found to render the BBB leaky to tracers including 
Evans blue albumin complex and radiolabeled iodide sodium in selected brain areas 
(Sharma and Dey, 1986; Sharma et al., 1991, 1992, 1995). Physical immobilization stress 
for 30 min was reported to increase BBB permeability to intravenously administered 
99Technetium gluceptate in the diencephalon and cerebellum (Esposito et al., 2001). In 
the same study, acute restraint stress was found to cause activation of brain mast cells. 
Also, enhanced BBB permeability in response to restraint was blocked by pretreatment 
with disodium cromoglycate, a mast cell stabilizer. The combined findings suggested 
immobilization might increase BBB penetrability through activation of brain mast cells. 
Stress activates the hypothalamic-pituitary-adrenal axis causing secretion of 
corticotropin-releasing hormone that in turn leads to release of glucocorticoids and 
catecholamines (White-Welkley et al., 1996; Dishman et al., 2000; Wong et al., 2000; 
Chennaoui, et al., 2002). Numerous studies suggested the enhanced release of stress 
hormones could elicit hippocampus injury or other neurotoxicity (Chan et al., 1996; 
17 
McIntosh and Sapolsky, 1996; Sapolsky, 1996; Bremner, 1999, 2001; Villarreal et al, 
2002). Deployment and operation during any war are obviously stressful events. The 
experience in the GW was not an exception. First, unfavorable living conditions ( e.g. 
change in diet, separation from family, isolation from the civilian society, etc) potentially 
enhanced psychological stress associated with war. Those conditions also included but 
were not limited to extreme weather in the battlefield in the Middle East, confinement in 
small camps and repeated military practice with little entertainment or recreation. 
Another severe stressor during the GW was apprehension about Iraqi military 
capabilities, such as the large fighting force, weapons of mass destruction, possible 
SCUD missile attacks on random targets and storage of highly lethal chemical and 
biological warfare agents with recognition of Iraq's past experience of using these agents 
in war time settings. In general, experience during the GW was a substantially stressful 
event to those military personnel, which may have led to deleterious effects in the 
nervous system as previously suggested, e.g., BBB disruption (Friedman et al., 1996). 
Chemical stressors such as some irreversible OP ChE inhibitors have been 
reported to increase BBB permeability to systemically administered tracers (Ashani and 
Catravas 1981; Carpentier et al., 1990; Grange-Messent et al., 1999). The exact 
mechanism of BBB breakdown by relatively high dose OP exposure is not clear, but is 
associated with induction of seizures with no remarkable changes in the structure of the 
tight junctions (Grange-Messent et al., 1999; Nitsch and Klatzo 1983). OP exposure was 
also previously reported to facilitate entry of peripherally-acting ChE inhibitor into the 
brain. Co-exposure of chlorpyrifos, a centrally-acting ChE inhibitor, with PYR led to 
greater inhibition of brain ChE and neurotoxic esterase activity than chlorpyrifos 
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exposure alone (Abou-Donia et al., 1996). The mechanisms for such interactive effects 
between chlorpyrifos and PYR are unclear. The results suggested, however, that OPs 
might increase BBB permeability to a peripherally-acting ChE inhibitor, therefore 
contributing to the synergistic ChE inhibition after carbamate and OP co-exposure. 
Ashani and Catravas (1981) reported that paraoxon, at dosages causing seizures, 
compromised BBB integrity and allowed the peripheral ChE inhibitor phospholine iodide 
to enter the brain. In general, according to these previous findings, relatively high dosage 
OP may alter the BBB and render the cerebral endothelial cell layer permeable to 
primarily peripherally-acting agents that have little access to the brain under normal 
conditions. Preliminary results suggested, however, that low dose paraoxon exposure 
associated with no seizures may also increase BBB permeability to the marker 
horseradish peroxidase (HRP). 
It has been widely accepted that PYR is a peripherally acting agent with little 
central effects. PYR, however, is not absolutely excluded from entering into the brain. 
Several studies suggested PYR with relatively high levels in the plasma could enter the 
brain causing observed CNS symptoms or functional changes. Loewenstein-Lichtenstein 
and co-workers (1995) demonstrated that high "effective" PYR levels resulting from the 
decreased detoxification capability of atypical BuChE caused severe CNS-associated 
symptoms. Results from Xia and colleagues (1981) suggested high dosage of PYR 
exposure (0.5 X LD50) associated with extensive plasma ChE inhibition caused slight 
ChE inhibition ( about 17%) in the brain. In our pilot study, the maximum tolerated 
dosage (MTD) of PYR (which caused more than 80% ChE inhibition in whole blood and 
diaphragm) inhibited about 20% ChE activity in the frontal cortex. Recently, repeated 
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treatment of PYR given at dosage of 1.85 mg/kg (i.p. injection) was also found to induce 
apoptotic cell death in cortex, hippocampus and striatum of rats (Li et al., 2000). PYR-
induced apoptosis was blocked by pretreatment with atropine, suggesting the apoptotic 
cell death was a muscarinic receptor mediated response. These results suggest that PYR, 
a ChE inhibitor limited to primarily peripheral actions, may penetrate into the brain and 
interact with other macromolecular targets but have little effect on the "primary'' target -
AChE. 
Several other studies reported interactions between PYR and muscarinic/nicotinic 
receptors. Using the patch clamp technique, PYR was found to interact with the ACh 
receptor-ionic channel complex, binding with the receptors as a weak agonist and 
inducing desensitization (Akaike et al., 1984; Albuquerque et al., 1984; Pascuzzo et al., 
1984). Sherby and co-workers (1985) observed displaced binding of 3H-ACh and 1251-
alpha-bungarotoxin to the ACh receptor sites by PYR pre-treatment. The bound PYR 
could act as a partial agonist and potentiate receptor desensitization (Santos et al., 2003). 
Therefore, it would be interesting to investigate the interaction of PYR with such 
additional targets (e.g. muscarinic and nicotinic receptors) in the brain, the subsequent 
pathological changes ( e.g. cell death, etc), and the effects of stress on those changes. 
Based on previous studies and our pilot findings, we hypothesized that physical or 
chemical stressors compromise BBB integrity and enhance PYR penetration into the 
brain. Enhanced CNS entry of PYR by stress may lead to increased neurotoxicity and be 
a contributing factor in unexplained GWI. 
To test our hypothesis, we proposed the following research objectives: 
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1) To determine the acute toxicity of PYR in immature male rats following oral 
dosing 
2) To evaluate the effects of either acute or repeated restraint stress on acute and 
subacute PYR toxicity 
3) To study the effects of acute restraint stress on BBB permeability 
4) To evaluate biochemical markers of stress following immobilization 
5) To study the effects of chemical stressor on PYR toxicity 
6) To investigate the effects of chemical stressor on BBB permeability 
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Chapter 2 
MATERIALS AND METHODS 
Animals 
Six-week old Sprague Dawley male rats were used for study of the effects of 
acute restraint stress on pyridostigmine toxicity while Sprague Dawley rats used for the 
study of repeated restraint stress were 5 weeks old at the start and 7 weeks old at the end 
of the experiment. For study of chemical stressors, 1) male Long Evans rats, 25-30 days 
of age, 2) male Sprague Dawley rats, 25-30 days of age, and 3) male Sprague Dawley 
rats, 6 weeks of age were used. Rats were maintained and handled according to 
NIH/NRC Guide for the Care and Use of Laboratory Animals and reviewed by the 
Institutional Animal Care and Use Committee at Oklahoma State University. Animals 
were acclimated for 7 days before experimentation and housed in a temperature and light 
controlled room (23±1C0 ; 12 h: 12 h, light: dark cycle). Rats were given free access to 
food and water and isolated from environmental stress throughout the acclimation and 
experimentation periods. 
Chemicals 
Peroxidase (type II, from horseradish, activity 158 units/mg), pyridostigmine 
bromide (PYR, 3-dimethylaminocarbonyloxy-N-methylpyridinium bromide), glucose 
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oxidase, 3,3 '-diaminobenzidine (DAB), and acetylcholinesterase (Type V-S) 
purified from electric eel were purchased from Sigma Chemical Company (St. Louis, 
MO). Paraoxon (0, O'-diethyl-0-(p-nitrophenyl) phosphate) was purchased from Chern 
Service (West Chester, PA). 3H-Acetylcholine iodide (specific activity= 82.0 rnCi/rnrnol) 
was obtained from New England Nuclear Company (Boston, MA). PYR and paraoxon 
were prepared in 0.9% saline fresh on the day of experiment and given by oral gavage 
and intra-muscular injection, respectively. DAB was prepared in a safety hood 
immediately before the start of the reaction for peroxidase histochemistry. All chemicals 
were reagent grade. 
Determination of the Maximum Tolerated Dosage of PYR and PHY 
Rats (n=6/treatrnent) were treated with one of four dosage levels of PYR (23, 30, 
39 and 50 mg/kg) and observed for functional signs of toxicity and lethality for 24 hours. 
The highest dosage of PYR associated with no lethality in treated rats was determined as 
the acute, oral maximum tolerated dosage (MTD) for the 6-week old male Sprague 
Dawley rats. The MTD of PHY was determined the same way except that rats were given 
PHY at the dosage of 11, 14.5, 19 and 25 mg/kg. 
Restraint Stress Protocols 
Rats were immobilized by placement in plexiglass cylindrical restrainers (Model 
#51336, Stoelting Research Instruments, Wood Dale, IL). Three protocols for the acute 
restraint stress model were designed as shown in Figure 6. Rats were either 1) placed in 
the restraint tubes for 90 min and immediately challenged with PYR, 2) treated with PYR 
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Acute Restraint Stress Protocols 
Time (min) 
0 60 90 150 180 240 
Pl ~ .. 
P2 i: 
p i: 
=> Restraint Period -+ PYR Exposure 
Figure 6: Acute restraint stress protocols. Protocol 1 (Pl): Rats were placed in the 
restraint tubes for 90 min followed by administration of PYR and placed back in the 
home cage for 60 min. Protocol 2 (P2): Rats were challenged with PYR and immediately 
placed into the restraint tubes for 60 min. Protocol 3 (P3): Rats were placed in the 
restraint tubes for 3 hrs, briefly removed, treated with PYR and replaced into the restraint 
tubes for an additional 60 min. 
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immediately before placing them into the restraint tubes for 60 min or 3) placed in the 
restraint tubes for 3 hrs, briefly removed, treated with PYR and replaced into the restraint 
tubes for an additional 60 min. In all three acute stress protocols, rats were given the 
MTD of PYR (30 mg/kg, p.o.) and observed for functional signs, i.e., SLUD (acronym 
for salivation, lacrimation, urination and defecation) and involuntary movements. Rats 
were sacrificed for collection of tissues at 60 min after PYR dosing. For repeated restraint 
studies, protocol 2 of acute stress was utilized on a daily basis for 14 consecutive days, 
i.e., rats were given PYR (0, 3 or 10 mg/kg/day, p.o.) and immediately placed in the 
restraint tubes for 60 min each day. SLUD signs and involuntary movements were scored 
daily at the termination of the restraint stress. In all acute and repeated restraint studies, 
rats were divided into four experimental groups with 6 rats per treatment group: 1) saline 
only (rats were kept in their home cage and treated with saline, 1 ml/kg, p.o.), 2) PYR 
only (rats were kept in their home cage and treated with PYR (in saline, 1 ml/kg, p.o.), 3) 
restraint only (rats were immobilized in one of the above stress protocols and given 
saline, p.o.), and 4) restraint+ PYR (rats were immobilized and given PYR, p.o.). 
Chemical Stress Protocols 
Three chemical stress protocols were designed as shown in Figure 7. In protocol 
1, male 25 to 30 day-old Long Evans rats were given either PYR (30 mg/kg) or saline by 
oral gavage. Paraoxon (100 µg/kg) or vehicle was injected in the thigh muscle 50 min 
after PYR exposure. Rats were .~acrificed 10 min after paraoxon treatment for tissue 
collection. In protocol 2, male 6-week old Sprague Dawley rats were treated the same as 
the Long Evans rats except the dosage ofparaoxon was 220 µg/kg. In protocol 3, male 25 
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Chemical Stress Protocols 
Time (min) 
0 50 60 
PYR Paraoxon Ci=---=-==================~~=======--------~·~ 
P J Lorig Evans, 25 to 30-day old 
P 2 Sprague Dawley, 6-week old 
P 3 Sprague Dawley, 25 to 30-day old 
100 µg/kg 
220 µg/kg 
120 µg/kg 
170 µg/kg 
220 µg/kg 
Figure 7: Chemical stress protocols. In all protocols, male rats were given PYR (30 
mg/kg, p.o.) for 50 min followed by paraoxon treatment (i.m. injection) for 10 min. In 
protocol I (Pl), 25 to 30 days old rats were used and the paraoxon dosage was 100 µg/kg. 
In protocol 2 (P2), 6 weeks old Sprague Dawley rats were used and paraoxon dosage was 
220 µg/kg. In protocol 3 (P3), 25 to 30 days old Sprague Dawley rats were given one of 
three levels ofparaoxon (120, 170 and 220 µg/kg). 
26 
to 30 day-old Sprague Dawley rats were given either PYR (30 mg/kg, p.o.) or saline. 
Three levels ofparaoxon (120, 170, or 220 µg/kg) were given 50 min after PYR. Tissues 
were collected 10 min after paraoxon. 
Functional and Behavioral Measurements 
Animals were observed by two investigators before sacrifice (i.e., 60 mm 
following PYR exposure) for involuntary movements and SLUD signs by the methods of 
Moser and coworkers (1988) as described before (Liu and Pope, 1996). Involuntary 
movements were scored as 2 = normal quivering of vibrissae, head and limbs; 3=mild, 
fine tremor typically seen in the forelimbs and head; 4=whole body tremor; 5=myoclonic 
jerks; 6=clonic convulsions. Autonomic dysfunction was scored as 1 =normal, no 
excessive secretion; 2=slight, one SLUD sign or very mild multiple signs; 3=moderate, 
multiple, over SLUD signs; 4=severe, multiple, extensive SLUD signs. 
AChE Activity Evaluation 
Regional brain (frontal cortex, cerebellum and hippocampus) and diaphragm 
samples were collected, dissected on ice and washed with saline to remove contaminating 
blood. Tissues were homogenized in 50 mM potassium phosphate (KPi) buffer (pH = 7) 
using a Polytron PT-3000 homogenizer (Brinkman Instruments, Westbury,NY) at 28,000 
rpm for 20 sec. Blood samples were collected in Eppendorf tubes (1.5 ml) containing 
heparin (20 µl, 10,000 units/ml) immediately after decapitation. All tissues were stored at 
-70°C, thawed and homogenized/diluted on the day of assay. AChE activity was 
measured radiometrically by the method of Johnson and Russell (1975) as previously 
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described (Pope et al., 1991) using 1 mM [3H]acetylcholine iodide as the substrate. 
Incubation times and tissue concentrations required for linear rates of substrate hydrolysis 
were confirmed in preliminary assays. The radiometric assay was conducted in 7 ml 
scintillation vials at room temperature. Following 60 µl of triton X-100 (1 % in 50 mM 
potassium phosphate buffer, pH=7.0), 20 µl of tissue homogenate were added, 20 µl of 
the hot substrate working solution was then added into the reaction mixture for a defined 
incubation time determined by preliminary study. "Stop" solution was then added to 
terminate the reaction followed by addition of 5 ml of scintillation solution. Reaction 
vials were vortexed thoroughly each time after solution was added. Capped vials were 
placed into a Wallac Liquid Scintillation Counter (Model 1409 DSA, PerkinElmer Inc., 
Boston, MA) for 2 min counting. Blank vials containing reaction solution but no tissue 
homogenate were also counted for the purpose of correcting for non-enzymatic 
hydrolysis of hot substrate. Reactions containing 20 µl of electric eel AChE (50 units/ml 
in phosphate buffer, pH 7) were also included for determination of the maximum 
hydrolysis of substrate. To minimize possible spontaneous reactivation of carbamylated 
ChE, conditions of limited tissue dilution and rapid assay following thawing and 
homogenization were adopted (Padilla and Hooper, 1992) as reported previously (Tian et 
al., 2002). Protein content was evaluated (Lowry et al., 1951) using 1 mg/ml bovine 
serum albumin as standard. Regional brain and plasma ChE activity was expressed as 
nmol/min/mg protein whereas blood AChE activity was expressed as nmol/min/µl blood. 
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Preparation of hot substrate 
A stock solution of radiolabeled acetylcholine iodide was made by suspension of 
1 mCi of [3H]acetylcholine iodide (specific activity RI 75 mCi/mmol) into 2 ml 50 mM 
potassium phosphate buffer (pH=7.0). The stock solution was kept at -70°C in the ultra 
low freezer. To make working solution of radiolabeled acetylcholine iodide, 95 µ1 of 
stock solution was thawed and transferred into clean vial followed by addition of 475 µ1 
of 24 mM non-radiolabeled acetylcholine iodide and 18.525 ml of 50 mM potassium 
phosphate buffer (pH=7.0). The final solution was 0.126 mM acetylcholine (specific 
activity of 3.944 µCi/µmol) and separated into 1 ml aliquots stored at -70°C until the 
time of ChE assay. 
Preparation of stop solution 
Stop solution was prepared by adding 9.45 g chloroacetic acid, 2 g sodium 
hydroxide and 11.6 g sodium chloride into distilled water with a final volume of 100 ml. 
Preparation of scintillation cocktail 
To prepare a liter scintillation cocktail solution, 5.0 g of PPO (2,5-diphenyl 
oxazole) and 0.3g of POPOP (1,4-bis[2-(5-phenyloxazolyl)]benzene) were dissolved in 
100 ml of isoamyl alcohol and diluted in toluene with a total volume of 1 liter. Solution 
was stirred with a magnetic bar in the hood overnight. 
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Lowry Protein Assay 
A standard curve of protein (0, 10, 25, 50, 75 and 100 µl of 1 mg/ml BSA) was 
included with each assay. For standard curve reactions, potassium phosphate buffer (pH 
7.0) was added to each mixture to a total volume equal to the tissue volume in the sample 
reaction tubes. The volume of diluted sample tissue added was determined such that the 
protein content would be less than 100 µg/ml which is the maximum concentration on the 
standard curve. The final volume for either standard reactions or sample reactions was 
adjusted to 200 µl with water. Two ml of working agent #1 was then added followed by 
vortexing. After 10 min at room temperature, 200 µl working reagent #2 was added. The 
tubes were then vortexed and allowed to stand 30 min at room temperature. Absorbance 
was measured at 720 nm in a Beckman UV-VIS Spectrophotometer (Beckman-Coutler, 
Fullerton, CA). 
Preparation of working reagents 
Working reagent #1 was prepared by mixing 1 part of 0.5% copper sulfate 
solution, 1 part of 1 % sodium potassium tartrate solution, and 100 parts of 2% sodium 
carbonate solution. Working reagent #2 was prepared fresh by mixing 1 part of folin 
phenol solution with 1 part of deionized water. 
Measurement of Stress Hormones 
For the acute restraint study, blood samples (n=6/treatment) were collected 
immediately, 1 and 3 hours following 60 min stress. For the repeated restraint study, 
blood samples (n=4/treatment) were collected immediately after removal from the 
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restraint tubes on days 1, 7 and 14. All procedures for collecting blood were completed 
within one minute to minimize hormone secretion caused by handling stress. Blood in a 
heparinized Eppendorf tube was immediately centrifuged (10,000 rpm, 1 minute at 4°C) 
to separate plasma, which was then frozen at -70°C until assay. Plasma corticosterone 
level was quantified using a radioimmunoassay kit (Rat Corticosteroid Coat-a-Count Kit, 
Diagnostic Products Corp., Los Angles, CA). 
PYR Treatment for Neuronal Cell Death Study 
Rats were given PYR (1.85 mg/kg, i.p.) every 12 hrs for 4 consecutive days as 
described by Li and colleagues (2000). Three hrs after the last dose, rats were perfused 
and fixed. Brains were collected, histochemically processed and evaluated for cell deaths 
under light microscope. 
Whole Body Perfusion for Neuronal Cell Death Study 
Rats were given a single injection of pentobarbital (50 mg/kg, i.p.). After being 
anesthetized, rats were fixed in dorsal recumbency on a rack in the pan. The thoracic 
cavity was opened by cutting from the left side of the sternum up to the level of the first 
rib. The sternum was reflected forward utilizing a hemostat clamp to expose the heart. 
Flushing solution began flowing at the rate of 40 ml/min. A blunted needle was inserted 
into the heart through the left ventricular apex towards the aorta. After the right heart was 
noted to bulge, the right atrium was lacerated with scissors. Blood, flushing solution and 
perfusate exited from the right side of the heart. Immediately following 60 sec perfusion 
with the flushing solution, fixative perfusion was started at the same pressure for 10 min. 
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Muscle twitching leading to whole body spasms was noted 1 to 2 min after start of the 
flowing of fixative indicating the systemic fixation of tissues. At the termination of 
perfusion, the whole rat body including the hind limbs was rigid as the indication of the 
quality perfusion. Brain was collected, processed and sliced for observation of cell death. 
Preparation of flushing solution 
For a volume of 1 L flushing solution, 1 ml heparin solution at the concentration 
of 1000 units/ml, 1 ml sodium nitrite solution (1 %), and 8.5 g sodium chloride were 
added into deionized water to make a total volume of 1 L. 
Preparation of fixative 
Fixative was prepared fresh on the day of experiment. Paraformaldehyde (30 g) 
and 2 to 3 drops of 5 N sodium hydroxide solution were added into 380 ml deionized 
water. Mixture was stirred and heated (but not to boil) until the paraformaldehyde 
dissolved. The clear solution was allowed to cool and then added to 120 ml 
glutaraldehyde (25%), 500 ml phosphate buffer, and 1 g picric acid. Solution was well 
mixed and filtered through a syringe. 
HRP Injection for BBB Permeability Evaluation after Restraint 
Immediately after being restrained for 60 min, rats were anesthetized with 
pentobarbital (50 mg/kg, i.p.). HRP (50 mg/ml) in saline containing 2% Evans blue was 
injected directly into the heart (2 ml/kg) by cardiac puncture over a 30-second period. 
Blue discoloration of the skin, eyes and tail within about 1 minute after the injection was 
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regarded as a positive indicator of systemic injection and only those rats were used for 
subsequent analyses. Rats were decapitated 10 minutes after HRP injection. Whole brain 
was removed and rinsed with saline. Frontal cortex, cerebellum, and hippocampus were 
dissected and stored at -70°C until assay. 
HRP Injection for BBB Permeability Evaluation after Paraoxon 
Chemical stress protocol 1 was chosen to study the effects of paraoxon on BBB 
permeability. Rats were given PYR (30 mg/kg, p.o.). Fifty min later, paraoxon (100 
µg/kg, i.m., 1 ml/kg) was injected in the thigh. At exactly 7.5 min after paraoxon 
treatment, rats were anesthetized by injection of xylak:et (14.2 ml of ethanol, 2.5 ml of 
xylazine at 100 mg/ml, and 25 ml of ketamine HCl at 100 mg/ml were diluted into 0.9% 
saline in a final volume of 100 ml). The thoracic cavity of the rats was then opened to 
expose the whole heart. Exactly ten min after paraoxon treatment, 200 µl HRP in 2% 
Evans blue solution (40 mg/1 ml, HRP: Evans blue) was injected into the left ventricle of 
each rat over a 10-sec period. The eyes, skin, feet and tail of the rats turned blue as the 
consequence of Evans blue circulating throughout the whole body. Rats were sacrificed 1 
min after the end of HRP injection. For ChE evaluation, rats were treated identically as 
above except that rats were not injected with HRP but sacrificed 10 min after paraoxon 
treatment. Whole brains were removed and cleaned of surface blood. Frontal and 
temporal cortex was dissected for ChE activity measurement. 
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HRP Biochemical Assay 
HRP activity was measured essentially by the method of Stewart and coworkers 
(1992) as reported previously (Tian et al., 2002). Regional brain tissues were 
homogenized in 50 mM sodium acetate buffer (pH = 5.0) using a Polytron PT-3000 
homogenizer for 20 seconds at 28,000 rpm. Samples (0.5 ml) were transferred to 
Eppendorf tubes (1.5 ml) and incubated with 0.1 ml 1% Triton X-100 in sodium acetate 
buffer for 20 minutes. Samples were vortexed twice during the 20 min incubation and 
centrifuged ( 4 min, 12,500 rpm, 4°C) following incubation. Reaction mixtures contained 
1 ml substrate (10 mg o-dianisidine HCI +0.5 ml deionized water+ 49 ml 50mM acetate 
buffer+ 0.5ml lOOmM EDTA), 16.6µ1 tissue sample and 20 µI 0.3% H20 2. Absorbance 
at 460 nm was determined every 30 seconds after the start of reaction for 2 minutes. HRP 
activity was expressed as ng HRP/mg tissue wet weight. 
HRP Histochemical Visualization 
The method of HRP visualization in the brain was essentially as described by 
Stewart and co-workers (1992). Brains were removed, surface blood was cleaned, and 
they were then placed overnight in glutaraldehyde (2.5% in 0.1 M phosphate buffer, pH 
7.4) followed by paraformaldehyde (4%) for at least 8 hours. Brains were then crude-
dissected and temporal and frontal cortex were collected separately and replaced in 
paraformaldehyde for histochemical evaluation. Fixed brains were sliced at 70 µm on a 
vibratome and kept in ice cold 10 µM PBS buffer. Sections were sequentially washed 
with 1) 10 µM PBS buffer, 2) paraformaldehyde (4%), 3) 10 µM PBS buffer, 4) twice 
with 0.1 M Tris buffer (pH 7.4) and then treated with 0.5% cobalt chloride in Tris buffer 
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for 10 min at room temperature. Sections were washed three times with 0.1 M Tris buffer 
(pH=7.4) and twice with 0.1 M phosphate buffer (pH=7.4). Substrate (100 ml phosphate 
buffer containing 50 mg diaminobenzidine (DAB), 40 mg ammonium chloride, 200 mg 
P-D-Glucose and 3 mg glucose oxidase) was added. Slices were incubated in the dark at 
37°C for 1 to 2 hrs untill a dark brown/black color was noted on the sections. Slices were 
mounted on glass slides and cover slips were positioned with 90% glycerol. Slides were 
dried for 10 min prior to observation under the light microscope (see below). 
Preparation of fixative for HRP histochemistry 
Solution of 0.4 M phosphate buffer was prepared first by adding 10.49 g sodium 
phosphate monobasic and 45.98 g sodium phosphate dibasic into 1 liter of water. Buffer 
was then well mixed and filtered to get the working solution. To make 1 liter 4% 
paraformaldehyde solution, 40 g paraformaldehyde was added into 400 ml deionized 
water and heated to 90°C for up to 45 min without boiling. A few drops of 10 M sodium 
hydroxide was added and the solution was then filtered using a filter syringe into 375 ml 
of 0.4 M phosphate buffer. Deionized water was then added to a final volume of 1 liter. 
BBB leakage Quantitation 
BBB disruption was visualized by HRP extravasation into the brain using light 
microscope. Eight sections from frontal and temporal cortex were selected for BBB 
leakage evaluation. Two investigators separately counted the HRP leaks under light 
microscope (1 OX magnification). Number of leaks observed on sections were 
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summarized and mean leaks/section was calculated for each of the frontal and temporal 
cortex. 
Dexamethasone Injection 
Male Long Evans rats (25 to 30 days old) were given 2 injections of 
dexamethasone (2 mg/kg, i.p.) with 24 hrs between the 2 treatments. Three hrs after the 
last dexamethasone injection, rats were given paraoxon (100 µg/kg, i.m.) followed by 
intra-cardiac injection of HRP 10 min later. Brains were collected 1 min after HRP 
perfusion and evaluated for HRP leakage in the frontal and temporal cortex. 
Corticosteroid Secretion after PYR Exposure 
Male Sprague Dawley rats (6-week old) were given MTD of PYR (30 mg/kg, 
p.o.). Whole blood was collected at 1, 2, 3, 6, and 24 hrs after PYR exposure. Plasma was 
separated and corticosteroid was measured by radioimmunoassay. 
Statistical Analysis 
Functional signs of toxicity were expressed as median ± interquartile range (IQR) 
and analyzed for significance by the Pearson Chi-square test. AChE activity was tested 
for significance by one-way or two-way analysis of variance (ANOV A). HRP activity 
was tested by one-way ANOV A followed by linear contrasts. HRP leakage ( calculated as 
leaks/section) was analyzed by two-way ANOV A followed by linear contrasts. Plasma 
corticosteroids levels were also tested by two-way ANOV A. All statistical analyses were 
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done with the JMP statistical computer software (SAS, 1995). In all cases, P value< 0.05 
was considered statistically significant. 
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Chapter 3 
RESULTS 
Part I: Effects of Physical Stress on PYR-induced Cholinergic Toxicity 
Maximum Tolerated Dosage of PYR and Physostigmine 
Table 2 demonstrates lethality in the 6-week old rats following PYR or 
physostigmine (PHY) exposure. After treatment with PYR, no death was noted in rats 
given 23 or 30 mg/kg PYR while one death occurred within 24 hrs in the rats given 38.5 
or 50 mg/kg. After PHY treatment, all rats given 11 mg/kg survived while 1 death was 
noted within 24 hrs in rats given 14.5 and 19 mg/kg and 2 deaths in 25 mg/kg. The acute 
oral MTDs of PYR and PHY in 6-week old male Sprague Dawley rats were therefore 
estimated at 30 and .11 mg/kg (in saline, 1 ml/kg), respectively. 
Timecourse and Dose-response of ChE Inhibition Following PYR or PHY 
Figure 8 illustrates inhibition of whole blood ChE activity from 0.5 to 24 hrs 
following PYR exposure (30 mg/kg, p.o.). Peak inhibition occurred from 0.5 to 4 hours 
after dosing, and less than 50% of control activity was still noted at 24 hrs after treatment. 
There was a slight (<20%) but significant reduction of frontal cortex ChE activity at both 
1 and 2 hr following PYR exposure. Figure 9 shows dose-related inhibition of blood ChE 
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activity 1 hr after PYR dosing, with an estimated ED50 of 3 mg/kg. As expected, lower 
dosages of PYR had little effect on cortical ChE activity. Figure 10 shows the in vitro 
inhibition of brain ChE activity by PYR. ChE inhibition increased in a concentration 
dependent manner with an IC50 of 0.66 µM (95% CI =0.4 to 1.1 µM). 
Figures 11 and 12 show the timecourse of ChE inhibition following MTD dosing 
and dose-response evaluation following PHY exposure. Both blood and brain ChE was 
significantly inhibited by PHY as shown in Figure 11. Inhibition occurred rapidly after 
PHY dosing, with 50% inhibition noted at 15 min following treatment. ChE activity 
started to recover from 2 hrs after exposure and nearly all activity recovered by 24 hrs 
after treatment. More extensive dose-related inhibition of brain ChE occurred after PHY 
than after PYR as noted in Figure 12, presumably due to the ability of PHY to penetrate 
into the brain through the BBB. 
These results confirm that PYR is essentially a peripherally-acting anti-ChE agent 
with limited effects on ChE activity in the frontal cortex, even at the highest dosage level 
(30 mg/kg, p.o.) that rats could tolerate (i.e., the MTD). However, brain ChE was 
sensitive to PYR in vitro. 
Functional Toxicity Measurements 
Figures 13 to 15 illustrate the effects of acute restraint stress on functional signs 
of cholinergic toxicity, i.e., SLUD and involuntary movements (IM), following the MTD 
of PYR. Rats ( either stressed or non-stressed) treated with PYR showed only moderate 
signs of cholinergic toxicity (SLUD ranged from 2 to 2.5, IM ranged from 3 to 3.25). 
None of the acute stress protocols, however, influenced PYR-induced toxicity since the 
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PYR-treated rats under restraint stress showed similar levels of toxicity as those without 
stress. Figures 16 to 19 illustrate the effects of daily restraint stress (60 min) on functional 
signs of toxicity in rats dosed daily with PYR (0, 3 or 10 mg/kg PYR) for 14 days. Rats 
(either stressed or non-stressed) given PYR (either 3 or 10 mg/kg, p.o.) initially exhibited 
SLUD signs and IM in the first 3 to 5 days of dosing, after which no functional signs 
were noted suggesting the development of tolerance. The degrees of toxicity signs for 
stressed PYR-treated rats and unstressed PYR-treated rats were similar, however 
suggesting repeated restraint stress had no apparent effects on PYR toxicity. 
ChE Activity 
Figures 20 to 41 show the effects of acute or repeated PYR exposures on ChE 
activity in central (frontal cortex, cerebellum and hippocampus) and peripheral (blood 
and diaphragm) tissues in the acute and repeated stress studies. All the ChE activities 
were expressed as % of control and summarized in Table 3. In general, PYR caused 
substantial inhibition of ChE activity in peripheral tissues, while having minimal and 
inconsistent effects on brain regional ChE activity. Acute PYR exposure in the acute 
restraint study caused marked inhibition of whole blood ChE activity (86-95%). Daily 
PYR exposure (3 or 10 mg/kg) for 14 days caused marked inhibition (52-85%) in 
peripheral tissues (whole blood and diaphragm) but little change in brain regional ChE 
activity. None of the acute or repeated restraint procedures increased ChE inhibition by 
PYR in either peripheral or central tissues, however. 
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BBB Permeability Following Acute Restraint 
HRP accumulation in brain regions was used to evaluate the change of BBB 
permeability following acute stress (60 min restraint). Figure 42 shows that HRP activity 
was not increased in frontal cortex, cerebellum or hippocampus by prior restraint stress. 
Corticosteroid Levels 
Figure 43 shows the plasma corticosteroid levels in rats following 60 min restraint 
stress. Plasma corticosteroid level was increased significantly (greater than 6-fold) 
immediately after termination of restraint and returned to normal 1 hour later. Figure 44 
shows plasma corticosteroid levels in rats following repeated daily restraint stress of 1 hr. 
Corticosteroid level was significantly elevated immediately after termination of restraint 
on days 1 ( about 7-fold) and 7 ( about 4-fold), but not increased on day 14 of the study. 
These results suggest that both acute and repeated restraint models induced a significant 
stress response, and that tolerance to immobilization may eventually develop with daily 
restraint stress. 
Neuronal Cell Death after PYR Treatment 
Figures 45 to 4 7 show neurons in the hippocampus and cortex following repeated 
PYR (1.85 mg/kg, i.p., every 12 hrs for 4 days) exposure. Micrographs of brain slices 
with Hematoxylin-Eosin (H-E) staining demonstrated the viable neurons with intact cell 
membranes and normal nucleus. No cell deaths were noted in the slices of brain from rats 
treated repeatedly with this relatively high dosage PYR exposure. 
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Part II: Effects of Chemical Stressor on PYR Penetration into the Brain 
BBB Leakage Visualization after PYR/Paraoxon 
Figure 48 is the result of pilot study from our collaborator (Dr. J. Bressler, 
Kennedy Krieger Institute, Baltimore, MD) showing BBB leakage visualized as the HRP 
extravasation from the cerebral capillaries into rat brain 10 min after paraoxon (100 
µg/kg, i.m.). Figures 49 to 52 illustrate HRP leaks (as indicated with black solid arrows) 
in the cortex after paraoxon and/or PYR exposure (treatments described in methods). 
Sporadic HRP leaks were noted in brain slices from control rats, which was considered as 
the baseline of HRP leakage in normal rats. Single high dose PYR treatment caused no 
apparent increase of HRP leaks. Diffuse leaks were observed, however in frontal and 
temporal cortexes of the rats given a single paraoxon dose (100 µg/kg, i.m.). 
Interestingly, only a few HRP leaks were noted in the brain slices of rats following PYR 
and paraoxon co-exposure, similar to that seen in the control or PYR-only groups. These 
results suggest paraoxon-associated HRP leaks were blocked by PYR pre-treatment. 
Quantitation of BBB Leakage after PYR/Paraoxon 
Figures 53 and 54 show the BBB disruptions quantified by the amount of HRP 
leaks in frontal and temporal cortex following PYR, paraoxon or both. Baseline BBB 
leakage ( about 6 leaks/section) was noticed in the brain of control rats. Sporadic BBB 
leaks (about 10 leaks/section) with relatively similar changes as in the control group were 
found in brain of the rats given a single dose of PYR. Relatively low dosage paraoxon 
(100 µg/kg, i.m.) elicited significantly higher number ofHRP leaks into the brain (20, 24 
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leaks/section in frontal and temporal cortex, respectively). BBB leakage (5, 11 
leaks/section in frontal and temporal cortex, respectively) of the rats following PYR and 
paraoxon co-exposure, however, was significantly lower than that in the rats treated with 
paraoxon only. These results suggest that paraoxon exposure induces significant BBB 
leakage in both frontal and temporal cortex. The paraoxon-induced HRP leaks into the 
brain were, however, at least partially blocked by the PYR pre-exposure. 
Functional and Behavioral Measurements 
Figure 55 shows functional signs of toxicity in rats given PYR, paraoxon or both. 
Rats given high dose of PYR (30 mg/kg, p.o.) showed moderate signs of cholinergic 
toxicity (SLUD signs median score=2; involuntary movement median score=3). Rats 
showed no overt signs of toxicity following paraoxon exposure (100 µg/kg), however. 
Rats also showed minimum but significant signs of toxicity following PYR and paraoxon 
co-exposure (SLUD signs median score=2; involuntary movement median score=3) with 
the toxicity scores similar to those noted in rats treated with PYR only. These results 
suggest that low dosage of paraoxon caused no cholinergic toxicity while a high dosage 
of PYR elicited moderate signs of toxicity. Paraoxon did not, however, influence PYR-
induced SLUD signs or involuntary movements. 
ChE Activity 
Figures 56 to 59 demonstrate ChE activity in the frontal cortex, temporal cortex, 
blood, and diaphragm following PYR, paraoxon or both in chemical stress protocol 1. For 
peripheral tissues, PYR caused remarkable ChE inhibition (>80%) while paraoxon 
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inhibited 40 to 65% ChE activity in whole blood and diaphragm. PYR and paraoxon 
combined exposure also caused more than 80% ChE inhibition in blood and diaphragm, 
which was similar as the inhibition levels following PYR only. For central tissues, PYR 
had little inhibitory effects on either frontal or temporal ChE activity. Paraoxon exposure 
caused 54-58% ChE inhibition in frontal and temporal cortex. PYR and paraoxon co-
exposure caused 40 to 42% ChE inhibition in frontal and temporal cortex. These results 
suggest relatively low dose of paraoxon (100 µg/kg, i.m.) inhibited about 50% of total 
ChE activity in the brain, however, paraoxon and PYR co-exposure did not elicit more 
extensive brain ChE inhibition. In fact, PYR pre-exposure appeared to block some degree 
ofChE inhibition caused byparaoxon (see Figure 57). 
Figures 60 to 64 illustrate ChE activity in frontal cortex, cerebellum, 
hippocampus, whole blood and diaphragm after PYR, paraoxon or both in chemical stress 
protocol 2. PYR had little effect on central ChE activity while paraoxon (220 µg/kg) 
caused about 50% ChE inhibition in frontal cortex and cerebellum. Rats treated with both 
PYR and paraoxon had similar brain ChE inhibition ( 45-49%) as noted in rats treated 
with paraoxon alone. PYR caused 87-88% inhibition while PYR and paraoxon co-
exposure caused 90-93% ChE inhibition in the whole blood and diaphragm. The two 
inhibition levels were statistically similar. Results suggested paraoxon did not facilitate 
PYR-induced ChE inhibition in the brain or peripheral tissues. 
Figures 65 to 68 demonstrate ChE activity in frontal cortex, cerebellum, 
hippocampus and whole blood after PYR, paraoxon or both in chemical stress protocol 3. 
PYR treatment did not lead to ChE inhibition in the central tissues. Paraoxon at 3 
different dose levels caused 48 to 75% ChE inhibition in cortex and cerebellum. Brain 
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ChE inhibition (44-72%) after co-exposure to PYR and each of the 3 levels of paraoxon 
was similar as that noted after the paraoxon exposure alone, which suggests paraoxon did 
not increase the PYR-induced brain ChE inhibition. Blood ChE inhibition (87%) after 
PYR dosing was relatively similar to that after PYR and paraoxon co-exposure (95%). 
Therefore, paraoxon and PYR did not appear to interact to yield different levels of ChE 
inhibition compared to individual chemical treatments. 
In summary, in all chemical stress protocols, paraoxon did not apparently enhance 
PYR penetration into the brain or influence the degree of PYR-induced ChE inhibition in 
any tissues. 
Effects of Dexamethasone on BBB Leakage 
Figure 69 shows the effect of dexamethasone on BBB leakage caused by 
paraoxon exposure. Dexamethasone alone (2 mg/kg, 2 injections) induced baseline HRP 
leaks (6 leaks/section) in the brain similar to that noted in control rats (7 leaks/section). 
Paraoxon (100 µg/kg) consistently elicited increased HRP leakage (16 leaks/section). 
Rats pre-treated with dexamethasone before paraoxon exposure showed baseline HRP 
leaks. The results suggested that dexamethasone pre-exposure could block the paraoxon-
induced BBB disruption. 
Corticosteroid Secretion after PYR Exposure 
Figure 70 shows time-dependent effects of PYR on corticosteroid secretion. PYR 
(30 mg/kg, p.o.) significantly increased plasma corticosteroid levels at 1, 2 and 3 hrs 
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(greater than 10 times control levels). Corticosteroid secretion returned back to normal 
levels 6 hrs after PYR dosing. 
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Table 2: Determination of the maximum tolerated dosage of PYR and PHY in 6-week 
old male Sprague Dawley rats. 
A. Lethality after PYR exposure 
Dosage (mg/kg) 23 30 38.5 50 
Death 0/6 0/6 1/6 1/6 
B. Lethality after PHY exposure 
Dosage (mg/kg) 11 14.5 19 25 
Death 0/6 1/6 1/6 2/6 
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Table 3: Influence of restraint stress on ChE inhibition following PYR exposure in rats. 
ChE Activity2 (% control ± SEM) 
Conditions Treatment1 
Cortex Cerebellum Hippo Blood Diaphragm 
Restrain-Trt Con-sal 100.0±6.5 100.0±4.7 100.0±2.5 100.0±3.3 
Con-PYR 90.6±10.8 99.6±9.1 93.6±5.0 9.5±1.2* 
Str-sal 93.6±9.4 99.9±4.4 91.4±4.4 84.1±7.9 
Str-PYR 103.2±5.1 83.0±4.5 101.6±5.5 7.7±0.7* 
Restraint/Trt4 Con-sal 100±3.3 100.0±6.4 100±2.3 100.0±5.8 
Con-PYR 79.8±4.7* 97.8±7.6 86.2±5.7 13.8±1.1* 
Str-sal 106.9±4.3 106.4±6.4 93.8±5.1 102.9±5.6 
Str-PYR 78.6±8.1* 88.3±2.5 93.0±6.8 12.8±0.6* 
Restrain-Trt/Restraint5 Con-sal 100.0±4.4 100.0±3.0 100.0±9.9 100.0±13.0 
Con-PYR 76.5±7.4 88.8±5.0* 108.7±3.0 4.9±0.7* 
Str-sal 96.7±5.1 111.4±5.5 110.1±7.4 96.5±8.6 
Str-PYR 81.0±11.1 78.3±3.4* 101.4±4.0 8.3±0.5* 
Repeated Con-sal 100.0±6.4 100.0±2.7 100.0±3.2 100.0±9.6 100.0±4.7 
Restraint(3~g/kg/day)6 Con-PYR 93.1±9.8 101.4±2.6 106.5±12.1 46.6±3.3* 23.3±1.6* 
Str-sal 110.3±4.7 100.3±2.1 99.3±9.2 110.9±6.6 96.9±6.1 
Str-PYR 111.0±7.0 106.2±4.6 98.4±2.8 46.5±3.2* 17.7±4.6* 
Repeated Con-sal 100.0±3.5 100.0±4.2 100.0±8.6 100.0±8.8 100.0±6.4 
Restraint( 1 Omg/kg/ day) 7 Con-PYR 96.3±2.7. 82.2±1.3* 92.1±10.7 19.8±2.0* 30.0±2.0* 
Str-sal 105.0±3.6 98.5±3.1 89.0±10.4 98.3±11.1 91.9±7.7 
Str-PYR 99.3±3.8 84.5±3.8* 87.5±5.5 15.4±1.8* 21.9±2.1 * 
1 For each experiment, 24 rats were divided into 4 groups with 6 rats per treatment: Rats were either not stressed 
(Con) or restraint-stressed (Str) and either given saline (sal) or pyridostigmine (PYR) 
2 ChE activity was measured by the radiometric method as described in Methods. Whole blood ChE activity was 
calculated as nmol/min/µl blood (combined control value: 0.48 ± 0.09) whereas regional brain and diaphragm 
ChE activity was calculated as nmol/min/mg protein (combined control value: frontal cortex, 39.2 ± 7.2; 
cerebellum, 20.6 ± 3.8; hippocampus, 24.2 ± 4.4; diaphragm, 4.3 ± 1.2). ChE activity was expressed as mean 
percentage of non-stressed, saline control group(± SEM). 
3Rats were restrained for 90 min, removed from restraint tubes and given PYR (30 mg/kg), and then sacrificed 1 h 
later for cholinesterase measurements. 
4Rats were given PYR (30 mg/kg), immediately placed in the restraint tubes and then sacrificed 1 hr later for 
cholinesterase measurements. 
5Rats were placed in restraint tubes for 3 hrs, removed and given PYR (30 mg/kg), replaced back into the restraint 
tubes for an additional ! hr and then sacrificed for cholinesterase measurements. 
6Rats were given PYR (3 mg/kg/day) and placed in the restraint tubes for 1 hr each day for 14 consecutive days. 
On the last day, rats were sacrificed immediately upon removal from the restraint tubes for cholinesterase 
measurements. 
7Rats were given PYR (10 mg/kg/day) and placed in the restraint tubes for 1 hr each day for 14 consecutive days. 
On the last day, rats were sacrificed immediately upon removal from the restraint tubes for cholinesterase 
measurements. 
*Asterisk indicates significant difference from Con-sal group. 
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Figure 8: Inhibition of ChE activity in whole blood and frontal cortex following 
maximum tolerated dosage of pyridostigmine bromide administration. Rats 
(n=6/treatment group) were treated with PYR (30 mg/kg, p.o. in saline) and sacrificed 
0.5, 1, 2, 4, 8 or 24 hrs following exposure. Frontal cortex and blood were collected for 
ChE activity measurement. ChE activity was measured by the radiometric method as 
described in Methods. Whole blood ChE activity was calculated as nmol/min/µl blood 
whereas frontal cortex ChE activity was calculated as nmol/min/mg protein. ChE activity 
was expressed as mean percentage of control group ± SEM. 
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Figure 9: In vivo dose-related ChE activity in frontal cortex and whole blood following 
PYR exposure. Rats (n=6/treatment group) were treated with PYR (0.1, 0.3, 1, 3, 10 or 
30 mg/kg, p.o.) and sacrificed 1 hr following exposure for measurement of ChE activity. 
Whole blood ChE activity was calculated as nmol/min/µl blood whereas frontal cortex 
ChE activity was calculated as nmol/min/mg protein. ChE activity was expressed as 
mean percentage of control group ± SEM. 
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Figure 10: In vitro concentration dependent frontal cortex ChE activity following PYR 
exposure. Rats frontal cortex was incubated with PYR with a series of concentrations 
(0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µM) at 37°C for 30 min 
and then measured for ChE activity. Frontal cortex ChE activity was calculated as 
nmol/min/mg protein. ChE activity was expressed as mean percentage of control group. 
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Figure 11: Inhibition of ChE activity in whole blood and frontal cortex following 
maximum tolerated dosage of physostigmine administration. Rats (n=6/treatment group) 
were treated with PHY (11 mg/kg, p.o. in saline) and sacrificed 15 min, 0.5, 1, 2, 4, 8 or 
24 hrs following exposure. Frontal cortex and blood were collected for ChE activity 
measurement. ChE activity was measured by the radiometric method as described in 
Methods. Whole blood ChE activity was calculated as nmol/min/µl blood whereas frontal 
cortex ChE activity was calculated as nmol/min/mg protein. ChE activity was expressed 
as mean percentage of control group ± SEM. 
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Figure 12: In vivo dose-related ChE activity in frontal cortex and whole blood following 
PHY exposure. Rats (n=6/treatment group) were treated with PYR (3, 5, 7, 9, 11 or 15 
mg/kg, p.o.) and sacrificed 30 min following exposure for measurement of ChE activity. 
Whole blood ChE activity was calculated as nmol/min/µl blood whereas frontal cortex 
ChE activity was calculated as nmol/min/mg protein. ChE activity was expressed as 
mean percentage of control group ± SEM. 
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Figure 13: Effects of acute restraint stress protocol 1 on PYR-induced cholinergic 
toxicity. Rats (n=6/treatment) were immobilized ( or not restrained) for 90 min and then 
given PYR (or saline) for 60 min. Rats were observed for functional signs of toxicity 
(SLUD signs and IM, reported as median ± IQR) before sacrifice. Asterisk indicates 
significant (p<0.05) difference from control group. 
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Figure 14: Effects of acute restraint stress protocol 2 on PYR-induced cholinergic 
toxicity. Rats (n=6/treatment) were given PYR (or saline) and immediately placed in 
restraint tubes ( or acclimation cage) for 60 min. Rats were observed for functional signs 
of toxicity (SLUD signs and IM, reported as median ± IQR) before sacrifice. Asterisk 
indicates significant (p<0.05) difference from control group. 
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Figure 15: Effects of acute restraint stress protocol 3 on PYR-induced cholinergic 
toxicity. Rats (n=6/treatment) were immobilized (or not restrained) for 3 hrs, given PYR 
( or saline) and replaced into the restraint tubes ( or acclimation cage) for an additional 60 
min. Rats were observed for functional signs of toxicity (SLUD signs and IM, reported as 
median ± IQR) before sacrifice. Asterisk indicates significant (p<0.05) difference from 
control group. 
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Figure 16: Effects of repeated restraint stress on PYR-induced SLUD signs of toxicity. 
Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline each day 
immediately prior to placement into restraint tubes or acclimation cage for 60 min over 
14 consecutive days. SLUD signs were recorded at the end of the 60 min restraint session 
each day and reported as median± IQR. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 17: Effects of repeated restraint stress ori PYR-induced IM signs of toxicity. Rats 
(n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline each day 
immediately prior to placement into restraint tubes or acclimation cage for 60 min over 
14 consecutive days. IM signs were recorded at the end of the 60 min restraint session 
each day and reported as median± IQR. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 18: Effects of repeated restraint stress on PYR-induced SLUD signs of toxicity. 
Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline each day 
immediately prior to placement into restraint tubes or acclimation cage for 60 min over 
14 consecutive days. SLUD signs were recorded at the end of the 60 min restraint session 
each day and reported as median± IQR. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 19: Effects of repeated restraint stress on PYR-induced IM signs of toxicity. Rats 
(n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline each day 
immediately prior to placement into restraint tubes or acclimation cage for 60 min over 
14 consecutive days. IM signs were recorded at the end of the 60 min restraint session 
each day and reported as median± IQR. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 20: Effects of acute restraint stress protocol I on PYR-induced ChE inhibition in 
frontal cortex. Rats (n=6/treatment) were immobilized (or not restrained) for 90 min and 
then given PYR ( or saline) for 60 min. Rats were sacrificed and frontal cortex was 
dissected for ChE activity. ChE activity was calculated as nmol/min/mg protein and 
expressed as mean percentage of control group ± SEM. 
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Figure 21: Effects of acute restraint stress protocol 1 on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment) were immobilized (or not restrained) for 90 min and 
then given PYR (or saline) for 60 min. Rats were sacrificed and cerebellum was dissected 
for ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as 
mean percentage of control group ± SEM. 
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Figure 22: Effects of acute restraint stress protocol I on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment) were immobilized (or not restrained) for 90 min and 
then given PYR ( or saline) for 60 min. Rats were sacrificed and cerebellum was dissected 
for ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as 
mean percentage of control group ± SEM. 
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Figure 23: Effects of acute restraint stress protocol 1 on PYR-induced ChE inhibition in 
whole blood. Rats (n=6/treatment) were immobilized (or not restrained) for 90 min and 
then given PYR ( or saline) for 60 min. Rats were sacrificed and blood was collected for 
ChE activity. ChE activity was calculated as nmol/min/µl blood and expressed as mean 
percentage of control group ± SEM. Asterisk indicates significant (p<0.05) difference 
from control group. 
64 
.-. 
- Cortex E 125 .. 
C 
0 
CJ 100 
~ 
._. 
>. 75 
.. 
·-> 
·-u 50 
<C 
w 25 
.c 
0 
0 
Control PYR Restraint Res+PYR 
Figure 24: Effects of acute restraint stress protocol 2 on PYR-induced ChE inhibition in 
frontal cortex. Rats (n=6/treatment) were given PYR (or saline) and immediately placed 
in restraint tubes ( or acclimation cage) for 60 min. Rats were sacrificed and frontal cortex 
was dissected for ChE activity. ChE activity was calculated as nmol/min/mg protein and 
expressed as mean percentage of control group ± SEM. 
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Figure 25: Effects of acute restraint stress protocol 2 on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment) were given PYR (or saline) and immediately placed in 
restraint tubes ( or acclimation cage) for 60 min. Rats were sacrificed and cerebellum was 
dissected for ChE activity. ChE activity was calculated as nmol/min/mg protein and 
expressed as mean percentage of control group ± SEM. 
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Figure 26: Effects of acute restraint stress protocol 2 on PYR-induced ChE inhibition in 
hippocampus. Rats (n=6/treatment) were given PYR (or saline) and immediately placed 
in restraint tubes ( or acclimation cage) for 60 min. Rats were sacrificed and hippocampus 
was dissected for ChE activity. ChE activity was calculated as nmoVmin/mg protein and 
expressed as mean percentage of control group ± SEM. 
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Figure 27: Effects of acute restraint stress protocol 2 on PYR-induced ChE inhibition in 
whole blood. Rats (n=6/treatment) were given PYR ( or saline) and immediately placed in 
restraint tubes ( or acclimation cage) for 60 min. Rats were sacrificed and blood was 
collected for ChE activity. ChE activity was calculated as nmol/min/µl blood and 
expressed as mean percentage of control group ± SEM. Asterisk indicates significant 
(p<0.05) difference from control group. 
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Figure 28: Effects of acute restraint stress protocol 3 on PYR-induced ChE inhibition in 
frontal cortex. Rats (n=6/treatment) were immobilized (or not restrained) for 3 hrs, given 
PYR ( or saline) and replaced into the restraint tubes ( or acclimation cage) for an 
additional 60 min. Rats were sacrificed and frontal cortex was dissected for ChE activity. 
ChE activity was calculated as nmol/min/mg protein and expressed as mean percentage 
of control group ± SEM. 
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Figure 29: Effects of acute restraint stress protocol 3 on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment) were immobilized ( or not restrained) for 3 hrs, given 
PYR ( or saline) and replaced into the restraint tubes ( or acclimation cage) for an 
additional 60 min. Rats were sacrificed and cerebellum was dissected for ChE activity. 
ChE activity was calculated as nmol/min/mg protein and expressed as mean percentage 
of control group ± SEM. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 30: Effects of acute restraint stress protocol 3 on PYR-induced ChE inhibition in 
hippocampus. Rats (n=6/treatment) were immobilized (or not restrained) for 3 hrs, given 
PYR ( or saline) and replaced into the restraint tubes ( or acclimation cage) for an 
additional 60 min. Rats were sacrificed and hippocampus was dissected for ChE activity. 
ChE activity was calculated as nmol/min/mg protein and expressed as mean percentage 
of control group ± SEM. 
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Figure 31: Effects of acute restraint stress protocol 3 on PYR-induced ChE inhibition in 
whole blood. Rats (n=6/treatment) were immobilized ( or not restrained) for 3 hrs, given 
PYR ( or saline) and replaced into the restraint tubes ( or acclimation cage) for an 
additional 60 min. Rats were sacrificed and blood was collected for ChE activity. ChE 
activity was calculated as nmol/µl blood and expressed as mean percentage of control 
group± SEM. Asterisk indicates significant (p<0.05) difference from control group. 
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Figure 32: Effects of repeated restraint stress on PYR-induced ChE inhibition in frontal 
cortex. Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline each 
day immediately prior to placement into restraint tubes or acclimation cage for 60 min 
over 14 consecutive days. Rats were sacrificed and frontal cortex was dissected for ChE 
activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. 
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Figure 33: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were sacrificed and cerebellum was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. 
74 
..-.. 
-E 125 
+"' 
C: 
0 
o 100 
~ C) 
.._.. 
~ 75 
+"' 
·-t, 
<( 
w 
.c 
0 
50 
25 
Hippocampus 
Control PYR Restraint Res+PYR 
Figure 34: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
hippocampus. Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were sacrificed and hippocampus was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. 
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Figure 35: Effects of repeated restraint stress on PYR-induced ChE inhibition in whole 
blood. Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline each day 
immediately prior to placement into restraint tubes or acclimation cage for 60 min over 
14 consecutive days. Rats were sacrificed and blood was collected for ChE activity. ChE 
activity was calculated as nmol/min/µl blood and expressed as mean percentage of 
control group ± SEM. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 36: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
diaphragm. Rats (n=6/treatment group) were given PYR (3 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were ~acrificed and frontal cortex was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 37: Effects of repeated restraint stress on PYR-induced ChE inhibition in frontal 
cortex. Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline each 
day immediately prior to placement into restraint tubes or acclimation cage for 60 min 
over 14 consecutive days. Rats were sacrificed and frontal cortex was dissected for ChE 
activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. 
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Figure 38: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
cerebellum. Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were sacrificed and cerebellum was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 39: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
hippocampus. Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were sacrificed and hippocampus was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. 
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Figure 40: Effects of repeated restraint stress on PYR-induced ChE inhibition in whole 
blood. Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline each 
day immediately prior to placement into restraint tubes or acclimation cage for 60 min 
over 14 consecutive days. Rats were sacrificed and blood was collected for ChE activity. 
ChE activity was calculated as nmol/min/µl blood and expressed as mean percentage of 
control group ± SEM. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 41: Effects of repeated restraint stress on PYR-induced ChE inhibition in 
diaphragm. Rats (n=6/treatment group) were given PYR (10 mg/kg/day, p.o.) or saline 
each day immediately prior to placement into restraint tubes or acclimation cage for 60 
min over 14 consecutive days. Rats were sacrificed and frontal cortex was dissected for 
ChE activity. ChE activity was calculated as nmol/min/mg protein and expressed as mean 
percentage of control group ± SEM. Asterisk indicates significant (p<0.05) difference 
from control group. 
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Figure 42: Accumulation of HRP in brain regions following acute immobilization stress. 
Rats (n=5-9/treatment group) were restrained for 60 minutes as described in Methods, 
immediately anesthetized with pentobarbital (50 mg/kg, i.p. injection) and horseradish 
peroxidase (in vehicle containing Evans blue dye) was injected by cardiac puncture 10 
minutes later. Rats were sacrificed 10 min after cardiac injection and brain regions 
(frontal cortex, cerebellum and hippocampus) dissected for measurement of peroxidase 
activity ( expressed as mean ± SEM). Only tissues from rats exhibiting systemic blue 
discoloration were used in the analyses. 
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Figure 43: Plasma corticosteroids following acute restraint stress. Rats (n=4/treatment) 
were restrained for 60 min. Plasma samples were collected from rats at 0, 1 or 3 hrs after 
termination of immobilization. Corticosteroids were measured by radioimmunoassay as 
described in Methods and calculated as ng/ml plasma. Asterisk indicates significant 
(p<0.05) difference from control group. 
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Figure 44: Plasma corticosteroids following repeated restraint stress. Rats (n=4/treatment) 
were restrained for 60 min each day for 14 consecutive days. Plasma samples were 
collected from rats immediately following 60 minutes immobilization on days 1, 7 and 
14. Corticosteroids were measured by radioimmunoassay as described in Methods and 
calculated as ng/ml plasma. Asterisk indicates significant (p<0.05) difference from 
control group. · 
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Figure 45: Light micrograph ( 40 X magnification) of neurons in hippocampus of rats 
following PYR exposure. Rats were injected with PYR (1.85 mg/kg, i.p.) every 12 hrs for 
4 days. Three hrs after last dosing, rats were purfused and fixed. Brains were removed, 
histochemically processed and evaluated for cell death by Hematoxylin-Eosin staining. 
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Figure 46: Light micrograph ( 400 X magnification) of neurons in brain of rats following 
PYR exposure. Rats were injected with PYR (1 .85 mg/kg, i.p.) every 12 hrs for 4 days. 
Three hrs after last dosing, rats were purfused and fixed. Brains were removed, 
histochemically processed and evaluated for cell death by Hematoxylin-Eosin staining. 
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Figure 47: Light micrograph (600 X magnification) of neurons in brain of rats following 
PYR exposure. Rats were injected with PYR (1.85 mg/kg, i.p.) every 12 hrs for 4 days. 
Three hrs after last dosing, rats were purfused and fixed. Brains were removed, 
histochemically processed and evaluated for cell death by Hematoxylin-Eosin staining. 
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Figure 48: Light micrograph of BBB disruption as visualized by HRP leakage (as 
indicated by black arrows) after chemical stress (paraoxon) exposure. Rats were given 
paraoxon (10 µg/kg, i.m.). Ten minutes later, rats were injected HRP through the left 
ventricle and circulation was allowed 1 min before sacrificing the rats. Brain were 
removed and fixed in 2.5% glutaraldehyde and sectioned at 70 µm. HRP was visualized 
by reaction with DAB. 
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Figure 49: Light micro graphs of HRP leaks in the coronal cortex sections of the control 
rats. Rats were given either vehicle or PYR (30mg/kg, p.o.) for 50 min followed by either 
vehicle or paraoxon (100 µg/kg, i.m.). Ten minutes later, rats were injected HRP through 
the left ventricle and circulation was allowed 1 min before sacrificing the rats. Brain were 
removed and fixed in 2.5% glutaraldehyde and sectioned at 70 µm. HRP was visualized 
by reaction with DAB. 
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Figure 50: Light micro graphs of HRP leaks (indicated with arrows) in the coronal cortex 
sections of the rats treated with single PYR. Rats were given either vehicle or PYR 
(30mg/kg, p.o.) for 50 min followed by either vehicle or paraoxon (100 µg/kg, i.m.). Ten 
minutes later, rats were injected HRP through the left ventricle and circulation was 
allowed 1 min before sacrificing the rats. Brain were removed and fixed in 2.5% 
glutaraldehyde and sectioned at 70 µm. HRP was visualized by reaction with DAB. 
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Figure 51: Light micro graphs of HRP leaks (indicated with arrows) in the coronal cortex 
sections of the rats treated with single paraoxon. Rats were given either vehicle or PYR 
(30mg/kg, p.o.) for 50 min followed by either vehicle or paraoxon (100 µg/kg, i.m.). Ten 
minutes later, rats were injected HRP through the left ventricle and circulation was 
allowed 1 min before sacrificing the rats. Brain were removed and fixed in 2.5% 
glutaraldehyde and sectioned at 70 µm. HRP was visualized by reaction with DAB. 
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Figure 52: Light micro graphs of HRP leaks (indicated with arrows) in the coronal cortex 
sections of the rats treated with both PYR and paraoxon. Rats were given either vehicle 
or PYR (30mg/kg, p.o.) for 50 min followed by either vehicle or paraoxon (100 µg/kg, 
i.m.). Ten minutes later, rats were injected HRP through the left ventricle and circulation 
was allowed 1 min before sacrificing the rats. Brain were removed and fixed in 2.5% 
glutaraldehyde and sectioned at 70 µm. HRP was visualized by reaction with DAB. 
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Figure 53: Blood-brain barrier disruption quantified by the number of HRP leaks in the 
frontal cortex after PYR, paraoxon or both. Rats were given either saline or PYR (30 
mg/kg, oral gavage) for 50 min and followed by either saline or paraoxon (100 µg/kg, 
i.m.) for 10 min. Rats were then injected with HRP (40 mg/kg) from the left ventricle and 
allowed circulation for 1 min before sacrifice. HRP leaks from the brain vessels into the 
brain parenchyma in each of 8 sections of frontal cortex slice were counted and 
calculated the mean leaks per section. Asterisk indicates significant difference (p < 0.05) 
from control rats while number sign indicates significant difference (p < 0.05) from 
paraoxon-treated rats. 
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Figure 54: Blood-brain barrier disruption quantified by the number of HRP leaks in the 
temporal cortex after PYR, paraoxon or both. Rats were given either saline or PYR (30 
mg/kg, oral gavage) for 50 min and followed by either saline or paraoxon (100 µg/kg, 
i.m.) for 10 min. Rats were then injected with HRP (40 mg/kg) from the left ventricle and 
allowed circulation for 1 min before sacrifice. HRP leaks from the brain vessels into the 
brain parenchyma in each of 8 sections of frontal cortex slice were counted and 
calculated the mean leaks per section. Asterisk indicates significant difference (p < 0.05) 
from control rats while number sign indicates significant difference (p < 0.05) from 
paraoxon-treated rats. 
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Figure 55: Score of the cholinergic signs of toxicity following PYR, paraoxon or both. 
Rats (n=l4/treatment) were given either saline or PYR (30 mg/kg) for 50 min and then 
given either saline or paraoxon (100 µg/kg) for 10 min. Rats were observed for SLUD 
signs and involuntary movement (IM) before sacrifice. Scores were expressed as median 
± interquartile range. Asterisk indicates statistically significant (p < 0.05) relative to 
control rats. 
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Figure 56: ChE activity in the frontal cortex after PYR, paraoxon or both in chemical 
stress protocol 1. Twenty-eight rats at age of 25 to 30-day old were divided into 4 groups, 
control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR + 
vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = 7/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (100 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/mg 
protein. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 57: ChE activity in the temporal cortex after PYR, paraoxon or both in chemical 
stress protocol 1. Twenty-eight rats at age of 25 to 30-day old were divided into 4 groups, 
control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR + 
vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = ?/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (100 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/mg 
protein. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. Number sign indicates significant (p<0.05) difference from PO group. 
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Figure 58: ChE activity in the blood after PYR, paraoxon or both in chemical stress 
protocol 1. Twenty-eight rats at age of 25 to 30-day old were divided into 4 groups, 
control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR + 
vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = 7/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (100 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/ml 
blood. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 59: ChE activity in the diaphragm. after PYR, paraoxon or both in chemical stress 
protocol 1. Twenty-eight Long Evans rats at age of 25 to 30-day old were divided into 4 
groups, control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR 
+ vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = 7/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (100 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/mg 
protein. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 60: ChE activity in the frontal cortex after PYR, paraoxon or both in chemical 
stress protocol 2. Twenty-four Sprague Dawley rats at age of 6-week old were divided 
into 4 groups, control (rats given vehicle of PYR + vehicle ofparaoxon), PYR (rats given 
PYR + vehicle ofparaoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO 
(rats given PYR + PO). Rats (n = 6/treatment) were given either saline or PYR (30 
mg/kg) for 50 min. Rats were then given either saline or paraoxon (220 µg/kg) for 10 min 
before sacrifice. ChE activity was radiometrically measured and calculated as 
nmol/min/mg protein. ChE activity was expressed in the graph as mean percentage of 
control group ± standard error of the mean. Asterisk indicates significant (p<0.05) 
difference from control group. 
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Figure 61: ChE activity in the cerebellum after PYR, paraoxon or both in chemical stress 
protocol 2. Twenty-four Sprague Dawley rats at age of 6-week old were divided into 4 
groups, control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR 
+ vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = 6/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (220 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/mg 
protein. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 62: ChE activity in the hippocampus after PYR, paraoxon or both in chemical 
stress protocol 2. Twenty-four Sprague Dawley rats at age of 6-week old were divided 
into 4 groups, control (rats given vehicle of PYR + vehicle ofparaoxon), PYR (rats given 
PYR + vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO 
(rats given PYR + PO). Rats (n = 6/treatment) were given either saline or PYR (30 
mg/kg) for 50 min. Rats were then given either saline or paraoxon (220 µg/kg) for 10 min 
before sacrifice. ChE activity was radiometrically measured and calculated as 
nmol/min/mg protein. ChE activity was expressed in the graph as mean percentage of 
control group ± standard error of the mean. Asterisk indicates significant (p<0.05) 
difference from control group. 
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Figure 63: ChE activity in the whole blood after PYR, paraoxon or both in chemical 
stress protocol 2. Twenty-four Sprague Dawley rats at age of 6-week old were divided 
into 4 groups, control (rats given vehicle of PYR + vehicle ofparaoxon), PYR (rats given 
PYR + vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO 
(rats given PYR + PO). Rats (n = 6/treatment) were given either saline or PYR (30 
mg/kg) for 50 min. Rats were then given either saline or paraoxon (220 µg/kg) for 10 min 
before sacrifice. ChE activity was radiometrically measured and calculated as 
nmol/min/ml blood. ChE activity was expressed in the graph as mean percentage of 
control group ± standard error of the mean. Asterisk indicates significant (p<0.05) 
difference from control group. 
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Figure 64: ChE activity in the diaphragm after PYR, paraoxon or both in chemical stress 
protocol 2. Twenty-four Sprague Dawley rats at age of 6-week old were divided into 4 
groups, control (rats given vehicle of PYR + vehicle of paraoxon), PYR (rats given PYR 
+ vehicle of paraoxon), PO (rats given vehicle of PYR + paraoxon), and PYR + PO (rats 
given PYR + PO). Rats (n = 6/treatment) were given either saline or PYR (30 mg/kg) for 
50 min. Rats were then given either saline or paraoxon (220 µg/kg) for 10 min before 
sacrifice. ChE activity was radiometrically measured and calculated as nmol/min/mg 
protein. ChE activity was expressed in the graph as mean percentage of control group ± 
standard error of the mean. Asterisk indicates significant (p<0.05) difference from control 
group. 
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Figure 65: ChE activity in the frontal cortex after PYR, paraoxon or both in chemical 
stress protocol 3. Sprague Dawley rats (25 to 30-day old, n = 6/treatment) were given 
either saline or PYR (30 mg/kg) for 50 min. Rats were then given either saline or 
paraoxon (120, 170 or 220 µg/kg) for 10 min before sacrifice. ChE activity was 
radiometrically measured and calculated as nmol/min/mg protein. ChE activity was 
expressed in the graph as mean percentage of control group ± standard error of the mean. 
Asterisk indicates significant (p<0.05) difference from control group. 
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Figure 66: ChE activity in the cerebellum after PYR, paraoxon or both in chemical stress 
protocol 3. Sprague Dawley rats (25 to 30-day old, n = 6/treatment) were given either 
saline or PYR (30 mg/kg) for 50 min. Rats were then given either saline or paraoxon 
(120, 170 or 220 µg/kg) for 10 min before sacrifice. ChE activity was radiometrically 
measured and calculated as nmol/min/mg protein. ChE activity was expressed in the 
graph as mean percentage of control group ± standard error of the mean. Asterisk 
indicates significant (p<0.05) difference from control group. 
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Figure 67: ChE activity in the hippocampus after PYR, paraoxon or both in chemical 
stress protocol 3. Sprague Dawley rats (25 to 30-day old, n = 6/treatment) were given 
either saline or PYR (30 mg/kg) for 50 min. Rats were then given either saline or 
paraoxon (120, 170 or 220 µg/kg) for 10 min before sacrifice. ChE activity was 
radiometrically measured and calculated as nmol/min/mg protein. ChE activity was 
expressed in the graph as mean percentage of control group ± standard error of the mean. 
Asterisk indicates significant (p<0.05) difference from control group. 
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Figure 68: ChE activity in the whole blood after PYR, paraoxon or both in chemical 
stress protocol 3. Sprague Dawley rats (25 to 30-day old, n = 6/treatment) were given 
either saline or PYR (30 mg/kg) for 50 min. Rats were then given either saline or 
paraoxon (120, 170 or 220 µg/kg) for 10 min before sacrifice. ChE activity was 
radiometrically measured and calculated as nmol/min/ml blood. ChE activity was 
expressed in the graph as mean percentage of control group ± standard error of the mean. 
Asterisk indicates significant (p<0.05) difference from control group. 
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Figure 69: Effects of dexamethasone (DXM) on paraoxon (PO)-elicited BBB disruption. 
Rats were given 2 injections of DXM (2 mg/kg, i.p.) with 24 hrs between the 2 
treatments. Three hrs after the last DXM injection, rats were given PO (100 µg/kg, i.m.) 
for 10 min followed by intra-cardiac injection of HRP. Brains were collected 1 min after 
HRP perfusion and evaluated for HRP leakage. Leaks were counted under the light 
microscope and calculated the mean leaks per section. Asterisk indicates significant 
difference (p < 0.5) from control rats while number sign indicates significant difference 
(p < 0.5) from PO-treated rats. 
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Figure 70: Time-dependent corticosteroid secretion after MTD of PYR treatment. Rats 
were treated with PYR at a dose of 30 mg/kg. Whole blood was collected at 1, 2, 3, 6, 
and 24 hrs after PYR administration. Plasma was separated and measured for the 
corticosteroid levels. Asterisk indicates significant difference from control (p < 0.05). 
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Chapter4 
DISCUSSION 
Effects of Physical Stress on PYR Toxicity 
The hypothesis that physical stress:s.induced changes in permeability of the BBB 
allowed PYR to enter the central nervous system and lead to persistent neurological signs 
and symptoms in GW veterans has attracted considerable attention in the past decade. In 
the present studies, we evaluated the effects of physical (restraint) or chemical (paraoxon) 
stressors on PYR cholinergic toxicity and BBB permeability. 
Physical stressors stimulate the hypothalamic-pituitary-adrenal axis resulting in 
the release of corticotropin releasing hormone leading to secretion of glucocorticoids and 
other hormones (Chrousos, 1995). In our physical stress studies, acute restraint and 
repeated restraint models elicited substantial elevation of plasma corticosteroids (see 
Figures 43 and 44), indicating the general validity of the stress models utilized. However, 
under a variety of stress-PYR interactive conditions (e.g., simultaneous stress and PYR, 
stress followed by PYR, short-term vs. long-term stress, acute stress/acute PYR vs. 
repeated stress/repeated PYR), we found little evidence of stress-related increased 
toxicity following PYR exposure. The results suggest that neither acute nor repeated 
restraint stress enhance ChE inhibition or cholinergic signs of toxicity following high 
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level PYR exposures. While the dosage of PYR utilized in acute studies was the highest 
level that could be tolerated without lethality and caused substantial ChE inhibition in 
peripheral tissues (i.e., diaphragm, whole blood), PYR had little direct anti-cholinesterase 
action in the brain. We did on occasion notice a slight reduction (11-22%) in ChE activity 
in some brain regions in our studies, e.g., frontal cortex of rats simultaneously restrained 
and given PYR for 1 hr, cerebellum of the rats exposed to 3 hrs restraint followed by 1 hr 
restraint and PYR co-treatment, and cerebellum of the rats exposed to daily 1 hr restraint 
and 10 mg/kg PYR co-treatment for 14 consecutive days (see Table 1). Although 
statistically significant, this degree of reduction in ChE activity would generally be 
considered to have little functional consequence (Nostrandt et al., 1997). More 
importantly, however, in those cases where minimal brain regional ChE inhibition was 
noted, the degree of inhibition was not increased by restraint stress. 
Besides using ChE inhibition as the biomarker for BBB permeability to PYR 
entrance, HRP accumulation in brain regions following systemic administration was 
measured to directly evaluate possible BBB permeability changes following acute 
restraint stress. While increased plasma corticosteroids levels following restraint stress 
suggested the procedures were indeed stressful to the animals, acute immobilization 
stress had no apparent effects on brain regional HRP activity (see Figure 42). Another 
study from our lab (Tian et al., 2002) obtained similar findings in studies evaluating 
treadmill running and forced swimming stressors. Together, these results suggest that 
physical stressors in rats have little effect on BBB permeability changes to either protein 
tracer (HRP) or a peripherally-acting ChE inhibitor (PYR). 
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Friedman and coworkers (1996) first reported a substantial effect of forced 
swimming stress on PYR-induced ChE inhibition in the brain of mice, showing that the 
anti-cholinesterase potency of PYR was increased over 100-fold by brief swimming 
stress episodes. Other indicators of enhanced entry of PYR into the brain ( e.g., increased 
brain levels of c-fos and AChE mRNA) were also reported. The discrepancies between 
our findings and those of Friedman and colleagues (1996) regarding the PYR-elicited 
ChE inhibition after stress could arise from a variety of factors, e.g., age of the animals 
and thus the maturational integrity of the BBB, strain of the animals, intensity or 
conditions of stress, etc. Among these considerations, the age of the animal model has 
been noted as a very important factor in sensitivity to possible BBB disruption by 
environmental factors. In previous studies showing BBB disruption after physical stress 
(Sharma and Dey, 1986; Ben-Nathan et al., 1989; Wijsman and Shivers, 1993), the 
animals used in the experiment were relatively young, with stress-associated BBB 
disruptions not noted in older animals. Of interest, while we found little BBB change 
under stressful conditions in young rats (5-7 weeks of age, an age group previously 
shown sensitive to BBB disruption with environmental stressors, Sharma and Dey, 1986), 
Friedman and colleagues (1996) reported BBB leakage after forced swim stress in adult 
mice. 
Intensity and duration of stress may also influence the change of BBB 
permeability. Previous studies showed a period of 30 min forced swim stress increased 
BBB permeability to Evans blue and 131iodide sodium, but 5 or 15 min forced swim stress 
failed to elicit the BBB leakage (Sharma et al., 1991). These results suggested certain 
stress conditions need to be met to exert effects on BBB permeability. 
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A strain-related difference in BBB integrity is another important factor in the 
controversy of the BBB response to stress and PYR exposure. The FVB/N mice that 
showed BBB leakage to forced swim stress in the previous study by Friedman and co-
workers (1996) was reported to have a "special" BBB, more permeable to penetrating 
agents compared to other strains (Wong et al., 1991; Telang et al., 1999). After 
inoculated with the tsl mutant of Moloney murine leukemia virus TB, all FVB/N mice 
developed hindlimb paralysis at 30-60 days post-inoculation, whereas only 33% of 
BALB/c mice developed hindlimb paralysis with a much longer latency period (Wong et 
al., 1991). Results suggested a strain-related difference in BBB resistance to 
environmental disruption. 
A result from Friedman's (1996) publication itself suggested the FVB/N mice 
have unusual BBB maturation. It was reported in the study that the ED50 of PYR for brain 
ChE inhibition ( dosage of PYR causing 50% ChE inhibition in the brain) is 100 fold less 
in stressed mice than in non-stressed mice. The presumption of the findings was that a 
single PYR exposure could indeed cause significant ChE inhibition (>=50%) in the brain 
of mice under un-stressed conditions, which is contrary to the well-established concept 
that PYR has little effect on brain ChE activity (Xia et al., 1981; Grauer et al., 2000; Li et 
al., 2000; Song et al., 2002; Tian et al., 2002). A number of studies have demonstrated 
that PYR should not enter the brain and elicit ChE inhibition to an extent of 50% even if 
administered at lethal dosage causing extensive ChE inhibition in peripheral tissues (Xia 
et al., 1981; Song et al., 2002; Tian et al., 2002). The PYR-elicited 50% ChE inhibition in 
the brain in Friedman's study (1996) suggested the mouse strain used in their 
experiments may have underdeveloped BBB. 
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Strain-related differences in sensitivity to PYR have been reported. Servatius and 
colleagues (1998) conducted an experiment to study exaggerated startle responses 
following PYR bromide exposure in Sprague Dawley and Wistar Kyoto rats. Both strains 
of rats were given PYR through the drinking water for 7 days. Sprague Dawley rats 
showed no response while Wistar Kyoto rats consistently demonstrated delayed 
exaggerated startle responses from 15 to 22 days after the last PYR treatment. Wistar 
Kyoto rats displayed a "come-sooner-go-faster" exaggerated startle response when they 
were treated with PYR for a second time. The remarkable difference between Sprague 
Dawley and Wistar Kyoto rats in response to PYR exposure was correlated with different 
levels of butyrylcholinesterase (BuChE) activity in the 2 strains, i.e., BuChE levels were 
significantly higher in Sprague Dawley than Wistar Kyoto rats. The enzyme was 
considered to serve as a scavenger or buffer for PYR and remarkably decreased the 
availability of PYR for possible penetration through the BBB. Therefore, the low level of 
BuChE activity in Wistar Kyoto rats may have increased the effective concentration of 
PYR in the circulation and thus the risk of PYR transport into the CNS and subsequent 
neurotoxicity. 
Another study (Loewenstein-Lichtenstein et al., 1995) suggested a genetic 
predisposition with abnormal plasma BuChE might render those soldiers more 
susceptible to the adverse effects of PYR. These authors reported that an Israeli soldier 
that was homozygous for the "atypical" BuChE showed severe neurological symptoms 
following PYR exposure. Atypical BuChE, the most common type of variant BuChE, 
was shown to be far less sensitive to PYR and other carbamate inhibitors than the wild 
type. It was proposed that reduced enzymatic hydrolyzing capability of the variant 
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BuChE resulted in higher levels of circulating PYR than in "normal" soldiers, which may 
subsequently cause adverse effects. The findings that less active BuChE may contribute 
to unexpected PYR toxicity may provide at least some information to the etiology of 
GWI. Those PYR pretreated soldiers who express atypical BuChE could have decreased 
detoxification of PYR and potentially higher plasma levels of PYR. To test this 
hypothesis, it would be necessary to conduct an epidemiological study to screen the 
BuChE in the soldiers given PYR and deployed in the Operation Desert Storm and Desert 
Shield and match the genetic screening results to the GWI symptom study. Studies need 
to address if soldiers have a significantly higher proportion of atypical BuChE variants 
and if there is a correlation between BuChE deficiency and the undiagnosed symptoms. 
However, disagreement with this hypothesis exists. Lotti and Moretto (1995) argued that 
the dose of PYR used in GW would be too low to saturate the scavenger capacity of the 
"atypical" BuChE to cause CNS dysfunction in soldiers with that variant enzyme. To 
clarify the possibility that genetic differences among BuChE variants cause adverse 
responses to ChE inhibitors, further investigations need to be conducted. 
Epstein and colleagues (1990) studied the effects of PYR on the 
thermoregulatory responses in human volunteers during exercise and heat stress. Given 
either placebo or PYR, young adult men were exposed to 170 min exercise (in order of 
60 min sitting, 50 min walking, 10 min rest and 50 min walking) and heat stress (33°C, 
relative humidity 60%). The physiological responses and heat balance parameters were 
similar between the placebo and PYR treated groups after exercise/stress exposure. 
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Arad and co-workers (1992) evaluated the effects of heat-exercise stress and PYR 
exposure on CNS functions of human volunteers. Results suggested there were no 
significant interactive effects between pyridostigmine and several stressors. 
Lallement and co-workers (1998) reported PYR did not penetrate into the brain of 
guinea pigs exposed to extreme heat stress. In their studies, guinea pigs were subjected to 
either a moderately or an extremely hot environment to maintain core temperature at 
41.5°C and 42.6°C respectively. PYR or tritiated PYR was injected 90 min after the heat 
stress. ChE activity in brain regions ( cortex, striatum and hippocampus) and radioactivity 
in brains (septum, caudate nuclei, hippocampus, thalamus and cortices) were measured to 
evaluate PYR penetration into the CNS. Results demonstrated 1) no brain ChE inhibition 
occurred regardless of the treatment or brain region, and 2) radioactive PYR was not 
detected in the CNS by autoradiographical analysis. 
Teland and co-workers (1999) also studied the penetration of radioactive PYR 
into the brains of mice under stressful conditions. Swiss-Webster male mice were 
subjected to 2 periods of 4-min forced swim stress with a 4 min interval between the 
stresses similar to study by Friedman and colleagues (1996). One microcurie of 11C-
labeled PYR was injected into the tail vein 10 min after the termination of the forced 
swim. Brains were taken out 10 min after the PYR injection and radioactivity was 
measured. The amount of 11C-labeled PYR in the brain following intravenous 
administration was not increased in mice following forced swimming stress. 
Grauer and coworkers (2000) investigated the effect of PYR on central ChE 
activity in mice after several stress models. In one experiment, male or female CD-1 
albino mice were subjected to either swimming stress (two 4-min periods of swim with a 
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2-min rest between the swimming sessions) or cold stress (a 5 min period with the mice 
feet placed in ice-cold water). PYR was given to the mice 10 min after the termination of 
the stress. Brains were collected 5 min after PYR exposure and ChE activity was 
measured. In another experiment, male FVB/n albino mice, the same mice strain used in 
Friedman et al (1996) and obtained from the same provider, were used to evaluate the 
interaction between stress and PYR. Results showed brain ChE activity was relatively 
similar in groups treated with PYR under either stressful or non-stressful conditions. 
Sinton and colleagues (2000) studied the interactions between PYR and physical 
stress in 2 rat strains using multiple stress protocols. Adult male Long Evans rats were 
exposed to forced swim stress (two 10-min sessions of forced swim with a 2-min rest 
interval), restraint stress (physically immobilized in restraint tubes for 30 min), or 
combined swim and restraint stress (in order of 10 min swim, 2 min rest, 10 min swim, 
30 min restraint, and 5 min swim). Adult male Wistar rats were exposed to only 
combined stress as used in Long Evans rats. PYR was given to rats 10 min after 
termination of the stress. Brains were removed 30 min after PYR treatment and ChE 
activity was measured. Data were similar across rat strain and stress protocols and 
suggested that brain ChE activity in PYR treated rats was actually higher under some 
stress conditions. These results suggest immobilization stress, forced swimming or 
combined stressors did not increase but actually reduced brain ChE inhibition by PYR. 
Ovadia and coworkers (2001) examined the effects of several stress models on the 
brain retention of circulating Evans blue dye as a biomarker of BBB disruption. Male 
Balb/c mice, FVB/n albinos, and male Sabra rats were used throughout the experiments. 
Animals were subjected to each of several stressors including the swim stress protocol 
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used in Friedman et al (1996) studies (i.e., two 4-min swim stress with a 4-min rest 
interval between), restraint stress (physical immobilization in restraint tube for 4 hrs), 
photic stimulus (flashes at the rate of 4/second for a 4 min period in the dark room), 
acoustic stress (bell ringing with the intensity of 109 dB for a 4-min period). Evans blue 
or 1251-albumin was injected into the heart of the rats 10 min after the completion of the 
stress procedure. Brains were collected 10 min after injection of tracers. Evans blue in the 
brains was measured spectrophotometrically and radioactivity of the 1251-albumin 
retained in brain tissues was counted in a gamma counter. The amount of circulatory 
tracers extravasated in the brains of the animals following various stress stimuli was 
similar to that of the non-stressed animals, suggesting none of the physical stress 
protocols influenced BBB permeability. Another important issue addressed in these 
studies is that insufficient washout of the blood vessels during the perfusion resulting in 
tracers left within the capillaries in the brains may cause misinterpretation of changes of 
BBB permeability. In other words, the apparent higher amount of tracers detected might 
be in fact the tracers in the cerebral vessels but not the tracers leaked into the brain 
parenchyma. The investigators also noted that at least 10 to 15 min washout is needed to 
ensure the cleanout of tracers from the cerebral capillaries while 1 min washing as that 
used in previous studies (Sharma et al., 1991) was not sufficient. 
Kant and co-workers (2001) studied the effects of footshock stress on PYR entry 
into the brain. Adult male Sprague Dawley rats were exposed to a 3-day long-term 
intermittent footshock and implanted with a mini-pump allowing slow release of PYR 
into the body. Brain ChE inhibition by PYR was not affected by the pre-exposure of 
footshock stress that significantly increased plasma corticosteroid level. Tian and co-
120 
workers (2002) investigated the effects of either forced swimming or treadmill running 
stress on acute PYR-induced functional toxicity and ChE inhibition in brain and blood of 
6-week old male Sprague Dawley rats. For the treadmill and PYR interaction study, rats 
were 1) treated with PYR and forced to run on the treadmill fro 20 min, 2) forced to run 
for 60 min, given PYR followed by another 30 min running, 3) forced to run for 90 min 
and then given PYR. For the forced swimming study, rats were 1) treated with PYR 
followed by swim stress for 15 min, 2) forced to swim for 15 min and treated with PYR. 
In all stress studies, rats were sacrificed for brains 1, 2 or 4 hours after PYR treatment. 
Results suggested neither treadmill running nor forced swimming influenced PYR 
associated brain-regional ChE inhibition or cholinergic toxicity. 
Therefore, a number of laboratories have evaluated the effects of a variety of 
physical stressors on the penetration of PYR or BBB passage tracers into the brain of 
multiple strains of mice, rats, or other species. The majority of these studies suggested 
that physical stressors generally have little influence on the ability of systemic PYR to 
interact directly with brain ChE or BBB permeability. 
Following Friedman and co-workers' findings (1996), Fishman (1997) argued that 
the BBB breakdown caused by forced swimming stress may not be a direct consequence 
of swim stress but a result of the hypertension associated with the forced swim stress. The 
author proposed that PYR may penetrate into the brain through the enlarged clefts 
between endothelial cells of the BBB in response to the mechanical stretch induced by 
high blood pressure. The forced swim stress may mask the effects of hypertension caused 
by itself and was thought to be the responsible factor to the BBB disruption. In other 
words, hypertension, which was caused by forced swimming may facilitate the PYR 
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entry into the brain causmg cholinergic toxicity, which may contribute to the 
development of GWI. If it were true that hypertension increases BBB permeability, it 
would be interesting and important to examine whether all physical stressors cause 
hypertension and in what animal models, and how to extrapolate the data from animals to 
humans. 
We concluded that physical stress does not markedly increase the entry of PYR 
into the brain. Environmental stressors, however, could modify the peripheral actions of 
PYR and lead to unexpected toxicity. Our results similar to findings from other 
laboratories, suggest that restraint stress has little effect on overt functional signs of 
cholinergic toxicity following high dosages of PYR. It is possible that stress could 
influence responses to lower dose PYR exposures, however. Nobrega and colleagues 
(1999) reported that comparatively low PYR exposure (45 mg dose, <1 mg/kg) reduced 
the heart rate increase associated with a mental stressor (arithmetic test) in healthy human 
volunteers. In another study, this same group (Nobrega et al., 2001) reported that 
repeated PYR dosing (30 mg every 8 hours) reduced heart rate and increased heart rate 
variability in healthy human volunteers over a 24-hour period. Plasma cholinesterase 
inhibition in this study was reported to be ~ 15% at 2 and 24 hours after initiation of 
dosing. Thus, more subtle peripheral effects may occur with very low dose PYR 
exposures associated with negligible inhibition of blood ChE. While blood ChE is 
generally more sensitive than AChE in "target" tissues, AChE in some autonomic 
pathways regulating cardiac function could possibly be more sensitive and inhibited by 
lower dosages of PYR. It may also be that another target macromolecule aside from 
AChE with higher sensitivity to PYR is responsible for the reported changes in cardiac 
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function. PYR has been shown to interact directly with nicotinic (Akaiki et al., 1984; 
Albuquerque et al., 1988) and muscarinic (Lockhart et al., 2001) receptors and such 
interactions could potentially be important in the observed modulation of cardiac 
function. Modulation of PYR-mediated chronotropic and heart rate variability changes by 
environmental stressors should be investigated. 
Haley and coworkers (1997) grouped the GWI into 6 syndromes. Two of these 
syndromes "confusion ataxia" and "arthro-myo-neuropathy," were significantly 
associated with self-reported adverse responses to PYR. The complaints were from the 
adverse experience with using of PYR but not the side effects of PYR exposure, 
suggesting veterans that served in GW may have different responses to the treatment of 
PYR and lead to the development of the illnesses complained by those veterans after 
GW. 
Substantial differences in PYR levels in plasma have been noted. First, the 
amount of PYR reaching the target enzyme is influenced by absorption and excretion. 
Individual differences in absorption of PYR result in a wide range of bioavailability of 
the drug. PYR-induced stimulation on gastrointestinal peristalsis influences its 
absorption. After PYR is absorbed, differences in the levels and types of metabolic 
enzymes influence the clearance of PYR. In summary, individual differences in ADME 
may lead to wide variations in the levels of PYR in the plasma (Cohan et al., 1977; 
Aquilonius et al., 1980). 
Variable responses to PYR have been noted. Li and co-workers (2000) found that 
brain ChE activity was not significantly inhibited by intra-peritoneal PYR exposures, but 
some treated rats showed substantial ChE inhibition. In our studies, we occasionally 
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noted up to 3 fold differences in the whole blood ChE inhibition after oral 30 mg/kg PYR 
(for example most rats showed greater than 90% inhibition while some showed 
approximately 30% inhibition). Additional, different degrees of PYR-elicited clinical 
toxicity signs of the rats within the same experimental groups were noted in some cases. 
Other studies showed a different duration of action by PYR, different PYR hydrolysis by 
ChE in presence of similar PYR levels in the plasma, etc. All the findings pointed to the 
existence of individual response to PYR anti-Cholinesterase effects. 
In summary, after PYR administration at the same dosage levels with same 
exposure route, it is likely that different responses occur with the different influence of 
one or more of the following events including absorption, metabolism of parent 
compound, clearance from the body, affinity and/or sensitivity to BuChE or AChE for 
hydrolysis. These factors could individually or cumulatively play a role in the 
development of differential toxicity, which may have developed as unexplained illnesses 
in more susceptible veterans. 
Effects of Chemical Stress on PYR Toxicity 
While the BBB appeared to be resistant to alteration by physical stressors, a 
number of studies reported BBB breakdown after exposure to chemical stressors, e.g. OP 
ChE inhibitor pre-exposure, or seizure eliciting agents. Ashani and Catravas (1981) 
reported soman or paraoxon exposure increased BBB permeability and allowed 
phospholine iodide, a peripherally-acting ChE inhibitor, to enter the brain and cause ChE 
inhibition. Carpentier and co-workers (1990) found that a high dosage of soman caused 
extravasation of injected Evans blue dye and endogenous immuno-protein lgG into the 
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brains of Wistar rats. Petrali and coworkers (1991) detected Evans blue, HRP and 
quaternary 3H-hexamethonium leaks in the brain after 0.9 X LD5o of soman. The exact 
mechanism for the BBB disruption after high dosage OP exposure is not clear. However, 
OP-induced BBB disruptions mentioned above were associated with seizures, which 
suggested OPs may compromise BBB integrity through eliciting convulsions and 
seizures. Sokrab and co-workers (1990) observed leaks of endogenous plasma albumin, 
fibrinogen and fibronectin in the brain after the induction of experimental seizures by 
intravenous bicuculline. Furthermore, the seizure-associated BBB leakages were 
significantly blocked by pre-treatment with anti-convulsive agents, e.g., nembutal or 
atropine sulfate (Ashani and Catravas, 1981). 
Our pilot findings suggested that relatively low dosage paraoxon (100 µg/kg, 
intra-muscular injection, 10 min exposure, causing about 50% brain ChE inhibition) 
could compromise BBB integrity, allowing the enzyme marker HRP to penetrate into the 
brain (See Figure 48). Using this "chemical stress" model, we investigated the effects of 
low dosage of paraoxon-elicited BBB opening on PYR toxicity. Interestingly, the results 
suggested that paraoxon-induced BBB leakage did not facilitate PYR entry into the brain. 
PYR elicited minimal signs of toxicity, but PYR-elicited toxicity was not increased by 
paraoxon (see Figure 55). Rather than a cumulative effect, combined pyridostigmine and 
paraoxon exposure resulted in lesser brain ChE inhibition than noted with paraoxon 
treatment alone. Relatively similar group-wise changes were noted in both frontal and 
temporal cortical regions. Moreover, paraoxon caused remarkable HRP leakage in the 
brain, but pre-exposure to PYR at least partially prevented the paraoxon-elicited BBB 
disruptions. One possible factor allowing PYR to block paraoxon-induced BBB 
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permeability might be related to the corticosteroid secretion in response to PYR 
exposure. Pretreatment with dexamathesone significantly reduced HRP leakage caused 
by paraoxon exposure (see Figure 69). Our current results confirmed several previous 
findings. Either a single injection or 3 daily treatments with dexamethasone significantly 
decreased the blood to brain transport of sucrose and alpha-aminoisobutyric acid in the 
brain of the rats (Ziylan et al., 1988, 1989). Dexamethasone was shown to decrease BBB 
permeability in rats experiencing ischemia, apparently through blocking the blood to 
brain transport of sodium ions (Betz and Coester, 1990). We found in our study that acute 
treatment with a high dosage of PYR caused remarkable elevation of corticosteroids in 
the plasma, and the stimulation lasted from 1 to 3 hrs after PYR challenge (See Figure 
70). We propose that the increased levels of corticosteroids after PYR dosing may 
decrease the BBB permeability to HRP penetration as that was noted in our PYR and 
paraoxon interaction study. Further studies need to investigate the effects of 
corticosteroid antagonists on the modulation of paraoxon-induced BBB disruption by 
PYR. Additional studies in adrenalectomized rats would also be interesting. Data from 
these studies could provide additional information of the relationship between PYR, 
corticosteroid secretion, and BBB permeability. 
Interaction of PYR and Some Pesticides Used During GW 
Our results suggested pararoxon and PYR have little additive or synergistic 
effects on central cholinergic toxicity. However, evidence exists to support the hypothesis 
that interaction of PYR with other chemicals causing synergistic toxicities might develop 
into unexplained illnesses in soldiers deployed in the GW. Considerable attention has 
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been given to the interaction between PYR and pesticides used by GW veterans. These 
pesticides include permethrin, DEBT and chlorpyrifos. 
Permethrin (3-(2,2-dichloro-ethenyl)-2, 2-dimethylcyclopropanecarboxylic acid 
(3-phenoxyphenyl) methyl ester) is a synthetic pyrethroid approved by the US EPA for 
use as an insecticide. Permethrin has been used to impregnate military uniforms. 
Permethrin affects multiple enzyme systems ( e.g., monoamine oxidase A and AChE) in 
the brain (Rao and Rao, 1993, 1995) and elicits toxicity signs including hyperactivity, 
ataxia, and tremor (McDaniel and Moser, 1993). DEBT (N, N-diethyl-m-toluamide), a 
widely-used commercial insect repellent, was used extensively by the US army during 
the GW. DEBT may cause toxicities such as ataxia, hypotension, coma and seizures (de 
Garbino and Laborde, 1983; Tenenbein, 1987). Chlorpyrifos (0, 0-diethyl 0-3, 5, 6-
trichloropyridinyl phosphorothioate ), an OP pesticide with inhibitory effects on ChE 
activity; elicits toxicities including SLUD signs, involuntary movements, tremors, 
memory and cognitive problems (Kaplan et al., 1993; Zheng et al., 2000). These three 
pesticides were all used during the GW and therefore could have potentially interacted 
withPYR. 
McCain and colleagues (1997) investigated acute toxicity after PYR, DEBT and 
permethrin co-exposure. Rats were treated with two of the three compounds at LD 16 
dosages (additive LD32) and the 3rd compound at varied dose levels (LDO, 16, 30, 50, 70 
and 84). PYR, permethrin, and DEBT given concurrently caused a significantly higher 
lethality than the predicted. Results from this study suggested that exposure to a mixture 
of PYR, permethrin and DEBT may lead to synergistic toxicity. 
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Abou-Donia and colleagues (1996a) investigated neurotoxicity after PYR, 
permethrin, and DEBT co-exposure in chickens. Each of the compounds elicited limited 
toxicity alone. Binary dosing, however, induced elevated neurotoxicity relative to 
individual compounds. Concurrent exposure to all 3 agents further increased 
neurotoxicity. The mechanism postulated for these interactive effects was that agents 
concurrently administered compete with each other for metabolism and result in 
decreased breakdown, thus increasing the availability for brain uptake. 
Abou-Donia and colleagues (1996b) also studied neurotoxicity after combined 
PYR, DEBT and chlorpyrifos exposure in chickens. ChE inhibition following combined 
exposures was higher than that after single compound exposures. Brain neurotoxic 
esterase (NTE) activity was not inhibited by any single agent or PYR and DEBT co-
exposure, but was significantly inhibited by combined treatment with chlorpyrifos 
(PYR/chlorpyrifos, DEET/chlorpyrifos, and PYRIDEET/chlorpyrifos). These results 
suggested that PYR, DEBT and chlorpyrifos co-exposure may lead to more extensive 
neurotoxicity. 
Recently, Abou-Donia and coworkers (2001) reported the effects of PYR, DEBT 
and permethrin on sensorimotor behavior and central cholingergic signal transduction 
pathways in rats. DEBT or permethrin, as single treatment or co-exposure, had no effects 
on motor activity while PYR, single dosing or in combination with DEBT and permethrin 
caused significant deficits in sensorimotor function. PYR and DEBT concurrent exposure 
or in addition with permethrin significantly inhibited the ChE activity in selected brain 
regions. Interactive effects of PYR and sarin on sensorimotor function in rats were also 
reported by Abou-Donia and colleagues (2002). Sensorimotor impairments caused by 
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single PYR or sarin exposures were increased if rats were exposed to both agents 
concurrently. 
Chaney and colleagues (2000) evaluated the effects of DEET on PYR-induced 
ChE inhibition in rats. While treatments of DEET or PYR alone had no effects on brain 
ChE activity, co-exposure of PYR and DEET induced significant ChE inhibition (40%) 
in the whole brain. Results suggested DEET potentiates PYR toxicity through facilitating 
PYR inhibition of brain ChE activity. 
Hoy and colleagues (2000 a) studied the alteration of locomotor behavior in rats 
after PYR, permethrin and DEET exposures. Male and female Sprague Dawley rats were 
given PYR, permethrin and DEET either individually or in combination. Single chemical 
treatments had limited effects on locomotor behavior. Binary treatments of PYR and 
permethrin at half of the single-drug dosing, however, significantly affected the 
locomotion rate. Hoy and colleagues (2000 b) also studied changes in locomotor behavior 
in rats after repeated co-exposure to PYR, permethrin and DEET. Rats were given PYR, 
permethrin and DEET individually or concurrently (2 of 3 compounds or all 3) on a daily 
basis for 7 consecutive days. Binary compound treatments significantly reduced 
locomotor activity, e.g., repeated PYR and DEET co-exposures significantly decreased 
the locomotion rate in male and female rats while repeated PYR and permethrin co-
exposure caused less thigmotaxis. These studies suggested an interactive effect between 
PYR, permethrin and DEET on locomotor behavior in rats. 
Van Haaren and co-workers (2001) evaluated the effects of PYR, permethrin and 
DEET on operant (fixed-ratio and fixed-interval) behavior in rats. Results suggested the 
existence of synergistic effects on the fixed-interval response in rats concurrently 
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exposed to PYR and permethrin or PYR and DEET binary treatments, all at a relatively 
low dose. 
Toxicity after PYR, permethrin and DEET exposure has been noted recently in 
the reproductive system (Abou-Donia et al., 2003). Rats were challenged with PYR, 
permethrin and DEET, either alone or concurrently for 4 weeks. Rats treated with all 3 
agents exhibited changes in the reproductive system, e.g., arrested spermatogenesis, 
thickened interstitium, vacuolization, and edema. In situ studies demonstrated apoptosis 
in the germ cells and spermatocytes. These changes were increased by daily stress 
(restraint) in rats treated with all 3 compounds. 
In general, a number of these studies suggest that PYR and the agents, e.g., DEET 
and permethrin, interact and could possibly contribute to the development of GWI. The 
mechanisms for the interactions and the extrapolation to humans remain to be addressed. 
Measurements of BBB Permeability 
Besides measuring and visualizing the intra-cardiac injected HRP in the brain, the 
classic and widely used method for evaluating BBB leakage, there are several other 
methods recently reported for the effective measurement of BBB permeability. 
S-lOOp, a brain-specific protein, is 3 times more concentrated in the cerebrospinal 
fluid than in the plasma. This protein leaks out of the brain and increases in plasma in the 
early stages of BBB disruption (Kapural et al, 2002). Agents causing a compromise of 
BBB integrity may increase S-1 oop protein transport across the BBB, in the opposite 
direction to HRP penetration as found in our study. Therefore, measurements of plasma 
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S-1 oop following either paraoxon alone or paraoxon plus PYR co-exposure could 
provide more information on the BBB permeability alterations following exposure to 
these toxicants. 
Sokrab and coworkers (1990) detected leakage of plasma protein e.g. albumin, 
fibrinogen and fibronectin in the brains after BBB disruption caused by a seizure-eliciting 
agent. Therefore measurement of plasma proteins in the brain could be employed to 
evaluate BBB integrity. 
Expression of endothelial barrier antigen (EBA) or blood-brain barrier protein in 
the cerebral endothelial cells has been related to the change of the BBB permeability by 
several research groups (Sternberger and Sternberger, 1987; Ghabriel et al., 2000; Abdel-
Rahman et al., 2002). EBA is selectively expressed in brain regions with endothelial 
barrier but not found in areas lacking the BBB such as median eminence, pineal gland 
and choroids plexus (Rosenstein et al., 1992; Sternberger and Sternberger, 1987). EBA is 
also absent in the endothelial cells of the peripheral organs including kidney, liver, and 
intestine, which have no blood to organ barrier. In general, EBA appears to be a marker 
antigen located at the luminal membranes of endothelial cells which express blood-organ 
barrier. Particularly, BBB disruption was associated with decreased level of EBA in the 
brain vasculature (Ghabriel et al., 2000; Abdel-Rahman et al., 2002). Therefore, 
immunocytochemical detection of EBA in brains could be an effective method used to 
"map" the BBB disruption after paraoxon/PYR exposure. 
Grauer and co-workers (2001) designed a novel method to estimate BBB 
permeability. A noninvasive but neurovirulent Sindbis virus systemically injected in mice 
causes viremia without CNS infection. A high virus titer was detected in the brain of 
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mice with BBB disruption, however. Results suggested Sindbis virus strain invasion 
could be utilized as a sensitive and reliable marker for BBB integrity. Computer based 
technologies such as CT and MRI have also been employed and reported effective in 
evaluation of BBB disruption (Tomkins et al., 2001; Harris et al., 2002). 
Multiple methods utilized to evaluate BBB permeability are considered important 
to provide accurate and confirmatory information forleakage following stressor exposure. 
The current methodologies for the measurement of BBB permeability after stress, 
however, were not consistently effective and sensitive for all animal models. Some may 
even be potentially problematic. Wijsman and Shivers (1993) reported that extravasation 
of peripherally injected HRP occurred in the brain of the rats following acute heat stress 
but no leakage of plasma Evans blue albumin complex was noted in the brain, which was 
contrary to the findings of many others (Sharma and Dey, 1986; Sharma et al., 1991, 
1992, 1995). As noted before, Ovadia and co-workers (2001) raised a critical issue in 
correct interpretation of BBB permeability studies. Their findings suggested that in order 
to accurately evaluate the BBB integrity by measuring the systemic Evans blue retained 
by the brain tissues after stress, sufficient perfusion time is necessary to clear out the dye 
retained in the lumen of the cerebral vasculature. Otherwise the apparently increased 
Evans blue detected might be the dye in the blood vessels in the brain and not the real dye 
leaked out of the blood and retained by the brain parenchyma. Thus, changes in vascular 
distention could bias interpretation of such marker studies. 
For the study of PYR inhibition of brain ChE activity, most of the findings 
suggest little inhibition in the brain of the animals under normal conditions or limited 
inhibition after physical stress exposure. In our studies, the MTD of PYR caused less than 
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20% ChE inhibition in brain regions (see Table 1). The limited ChE inhibition has 
insignificant effects on the functions related to cholinergic signal transduction (Nostrandt 
et al., 1997). On the other hand, if PYR penetration occurred in a small, confined area in 
the brain, measurement of ChE activity in large tissues could mask effects in small 
regions. This could have important consequences. There is precedence for sub-regional 
neurotoxicity, e.g., substantia nigra affected by MPTP, striatum by manganese (Zheng, 
2001). It has been demonstrated that the BBB is not uniformly resistant in different brain 
regions, which allows xenobiotics to penetrate into the CNS in a regional dependent 
manner. If the penetration of PYR also occurs in a regional-selective manner, closer 
examination of ChE inhibition in discreet regions may be informative. 
Besides inhibitory effects on ChE activity, PYR was also shown to cause 
apoptosis in the CNS or reproductive system (Li et al., 2000, 2001; Abou-Donia et al., 
2003). Li and co-workers (2000) reported apoptosis in the brain after repeated intra-
peritoneal injection of PYR (1.85 mg/kg, every 12 hrs for 4 days), but no significant ChE 
inhibition was noted in brain regions including cortex, hippocampus and striatum. The 
results suggested PYR entrance into the brain causing little ChE inhibition may elicit 
severe damage to neurons. It is therefore possible other injuries in the CNS could occur 
after PYR exposure without significant ChE inhibition in the brain. Therefore, a sensitive 
and specific method for measuring the change of PYR uptake across the BBB is needed. 
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Summary 
Physical stress elicits stressful responses as indicated by increasing corticosteroid 
levels in plasma. Whether physical stress enhances BBB permeability and allows PYR 
entry into the brain is still controversial. Our studies and most of the recent publications 
suggest, however, that physical stress is unable to enhance BBB penetrability or brain 
ChE inhibition by PYR. A number of methods have been employed to study the change 
of BBB permeability. Appropriate and sensitive evaluations are warranted to avoid 
misinterpretation. 
Paraoxon can compromise BBB integrity. Paraoxon-induced BBB leakage did not 
facilitate PYR entry into the brain. Interestingly, PYR pre-treatment blocked systemic 
HRP leakage into the brain caused by paraoxon. The mechanism for these novel findings 
may relate to PYR's ability to elevate corticosteroid levels. Further investigations remain 
to be conducted. 
PYR toxicity in CNS can not be ruled out as a contributing factor to the 
development of GWI. PYR may interact with pesticides (e.g., DEBT, permethrin and 
chlorpyrifos) and cause synergistic toxicity, which may potentially developed into 
unexplained GWI. PYR may cause alternative forms of injury, e.g., apoptotic cell death, 
in brain with little ChE inhibition. Therefore, future studies on PYR toxicity related to the 
negative health effects in veterans from GW would be interaction between PYR and other 
environmental agents, or toxicity caused by limited PYR in sensitive brain regions. 
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Chapter 5 
CONCLUSIONS 
1. The maximum tolerated dosage of PYR is 30 mg/kg (p.o.) for 6-week old male 
Sprague Dawley rats. 
2. PYR is a peripheral ChE inhibitor having little effects on brain ChE activity. The 
ED50 of PYR on whole blood ChE activity was about 3 mg/kg. 
3. Both acute and repeated restraint stress elicited stress response in Sprague Dawley 
rats as measured by elevated cortisol levels in plasma. 
4. Acute and repeated restraint stress had little effect on PYR-elicited cholinergic 
signs of toxicity and ChE inhibition in central and peripheral tissues. 
5. Acute restraint stress did not facilitate the penetration of horseradish peroxidase 
into the brain regions following systemic administration. 
6. Repeated PYR did not induce cell death in the brain. 
7. Low dosage paraoxon induced BBB leakage in young Long Evans rats. 
8. Paraoxon-induced BBB leakage did not increase PYR-elicited cholinergic signs 
of toxicity or ChE inhibition in brain regions or peripheral tissues. 
9. Paraoxon-induced BBB leakage was blocked by PYR pretreatment. 
10. Paraoxon-induced BBB leakage was blocked by dexamethasone pretreatment. 
11. PYR exposure significantly elevated corticosteroid levels in plasma. 
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